U.S. patent application number 11/900463 was filed with the patent office on 2008-06-12 for packaging systems for human recombinant adenovirus to be used in gene therapy.
This patent application is currently assigned to Crucell Holland B.V.. Invention is credited to Abraham Bout, Frits J. Fallaux, Robert C. Hoeben, Domenico Valerio, Alex J. van der Eb.
Application Number | 20080138901 11/900463 |
Document ID | / |
Family ID | 27669813 |
Filed Date | 2008-06-12 |
United States Patent
Application |
20080138901 |
Kind Code |
A1 |
Fallaux; Frits J. ; et
al. |
June 12, 2008 |
Packaging systems for human recombinant adenovirus to be used in
gene therapy
Abstract
Presented are ways to address the problem of
replication-competent adenovirus in adenoviral production for use
with, for example, gene therapy. Packaging cells having no
overlapping sequences with a selected vector are suited for large
scale production of recombinant adenoviruses. A described system
produces replication-defective adenovirus. The system includes a
primary cell containing a nucleotide derived from adenovirus and an
isolated recombinant nucleic acid molecule for transfer into the
primary cell. The isolated recombinant nucleotide is derived from
an adenovirus, has at least one functional encapsidation signal and
at least one functional Inverted Terminal Repeat, and lacks
overlapping sequences with the nucleic acid of the cell. Otherwise,
the overlapping sequences would enable homologous recombination
leading to replication-competent adenovirus in the primary cell
into which the isolated recombinant nucleotide is to be
transferred.
Inventors: |
Fallaux; Frits J.;
(Leiderdorp, NL) ; Hoeben; Robert C.; (Leiden,
NL) ; van der Eb; Alex J.; (Oestgeest, NL) ;
Bout; Abraham; (Moerkapelle, NL) ; Valerio;
Domenico; (Oegstgeest, NL) |
Correspondence
Address: |
TRASK BRITT
P.O. BOX 2550
SALT LAKE CITY
UT
84110
US
|
Assignee: |
Crucell Holland B.V.
Leiden
NL
|
Family ID: |
27669813 |
Appl. No.: |
11/900463 |
Filed: |
September 11, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11485114 |
Jul 12, 2006 |
|
|
|
11900463 |
|
|
|
|
10125751 |
Apr 18, 2002 |
7105346 |
|
|
11485114 |
|
|
|
|
09506548 |
Feb 16, 2000 |
6602706 |
|
|
10125751 |
|
|
|
|
09334765 |
Jun 16, 1999 |
6238893 |
|
|
09506548 |
|
|
|
|
08793170 |
Mar 25, 1997 |
5994128 |
|
|
PCT/NL96/00244 |
Jun 14, 1996 |
|
|
|
09334765 |
|
|
|
|
Current U.S.
Class: |
435/455 ;
435/325; 435/366; 435/369; 536/23.72 |
Current CPC
Class: |
C12N 2710/10351
20130101; A61K 48/0091 20130101; C12N 2710/10322 20130101; A61K
48/00 20130101; C12N 5/0621 20130101; C12N 2830/42 20130101; C12N
7/00 20130101; C07K 14/005 20130101; C12N 2710/10352 20130101; C12N
2710/10343 20130101; C12N 15/86 20130101 |
Class at
Publication: |
435/455 ;
536/23.72; 435/325; 435/366; 435/369 |
International
Class: |
C12N 15/87 20060101
C12N015/87; C12N 15/11 20060101 C12N015/11; C12N 5/06 20060101
C12N005/06 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 15, 1995 |
EP |
95201611.1 |
Jun 26, 1995 |
EP |
95201728.3 |
Claims
1. An isolated first nucleic acid molecule comprising genetic
information encoding functional adenovirus E1A, E1B 21 kDa and E1B
55 kDa gene products, wherein said first nucleic acid molecule
lacks genetic information from an adenovirus pIX gene that can
mediate homologous recombination with a second nucleic acid
molecule having genetic information encoding a functional or active
adenovirus pIX gene product, and further wherein said first nucleic
acid molecule lacks genetic information encoding adenovirus
proteins other than proteins encoded by adenovirus early region
1.
2. The isolated first nucleic acid molecule of claim 1, wherein the
isolated nucleic acid molecule comprises nucleotides 459-3510 of
Ad5.
3. The isolated first nucleic acid molecule of claim 2, wherein the
isolated nucleic acid molecule lacks nucleotides from the E1 region
of Ad5 downstream of nucleotide 3510.
4. The isolated first nucleic acid molecule of claim 1, further
comprising a promoter operatively linked to at least the genetic
information encoding the functional E1A gene product.
5. The isolated first nucleic acid molecule of claim 4, wherein the
promoter comprises a constitutive promoter.
6. The isolated first nucleic acid molecule of claim 5, wherein the
constitutive promoter comprises a PGK promoter.
7. The isolated first nucleic acid molecule of claim 4, wherein the
promoter comprises a human PGK promoter.
8. The isolated first nucleic acid molecule of claim 1, further
comprising the Hepatitis B Virus polyadenylation signal located
downstream of an E1B stop codon.
9. The isolated first nucleic acid molecule of claim 4, further
comprising the Hepatitis B Virus polyadenylation signal located
downstream of an E1B stop codon.
10.-18. (canceled)
19. An isolated adenovirus packaging cell comprising the isolated
first nucleic acid molecule of claim 1.
20. The isolated adenovirus packaging cell of claim 19, wherein the
cell is a mammalian cell.
21. The isolated adenovirus packaging cell of claim 19, wherein the
cell is a human cell.
22. The isolated adenovirus packaging cell of claim 19, wherein the
cell is a diploid cell.
23. The isolated adenovirus packaging cell of claim 19, wherein the
cell is derived from an embryonic cell.
24. The isolated adenovirus packaging cell of claim 23, wherein the
embryonic cell is selected from the group consisting of kidney
cells, lung cells, and retinoblast cells.
25. The isolated adenovirus packaging cell of claim 24, wherein the
embryonic cell is a retinoblast cell.
26. The isolated adenovirus packaging cell of claim 19, wherein the
cell is immortalized.
27. A method for making an isolated adenovirus packaging cell
comprising introducing into the cell the isolated first nucleic
acid molecule of claim 1.
28. The method according to claim 27, further comprising
integrating the isolated first nucleic acid molecule into the
precursor cell's genome.
29.-37. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application is a continuation of U.S. patent
application Ser. No. 11/485,114, filed Jul. 12, 2006, which
application is a continuation of co-pending U.S. patent application
Ser. No. 10/125,751, filed Apr. 18, 2002, U.S. Pat. No. 7,105,346,
issued Sep. 12, 2006, which is a continuation of application Ser.
No. 09/506,548, filed Feb. 16, 2000, now U.S. Pat. No. 6,602,706,
issued Aug. 5, 2003, which is a division of Ser. No. 09/334,765,
filed Jun. 16, 1999, now U.S. Pat. No. 6,238,893, which is a
continuation of Ser. No. 08/793,170, filed Mar. 25, 1997, now U.S.
Pat. No. 5,994,128, issued Nov. 30, 1999, which is a national entry
of PCT International Patent Application PCT/NL96/00244, filed Jun.
14, 1996, which itself claims priority from European Patent
Application EP 95201728.3, filed Jun. 26, 1995, and European Patent
Application EP 95201611.1, filed Jun. 15, 1995, the contents of
each of which are hereby incorporated herein by this reference.
TECHNICAL FIELD
[0002] The invention relates generally to the field of
biotechnology and recombinant DNA technology, more in particular to
the field of gene therapy. In particular, the invention relates to
gene therapy using materials derived from adenovirus, specifically
human recombinant adenovirus. It especially relates to novel
virus-derived vectors and novel packaging cell lines for vectors
based on adenoviruses.
BACKGROUND
[0003] Gene therapy is a recently developed concept for which a
wide range of applications can be and have been envisioned. In gene
therapy, a molecule carrying genetic information is introduced into
some or all cells of a host, as a result of which the genetic
information is added to the host in a functional format.
[0004] The genetic information added may be a gene or a derivative
of a gene, such as a cDNA, which encodes a protein. This is a
functional format in that the protein can be expressed by the
machinery of the host cell.
[0005] The genetic information can also be a sequence of
nucleotides complementary to a sequence of nucleotides (either DNA
or RNA) present in the host cell. This is a functional format in
that the added DNA (nucleic acid) molecule or copies made thereof
in situ are capable of base pairing with the complementary sequence
present in the host cell.
[0006] Applications include the treatment of genetic disorders by
supplementing a protein or other substance which, because of the
genetic disorder, is either absent or present in insufficient
amounts in the host, the treatment of tumors, and the treatment of
other acquired diseases such as (auto)immune diseases, infections,
etc.
[0007] As may be inferred from the above, there are basically three
different approaches in gene therapy: the first directed towards
compensating for a deficiency in a (mammalian) host, the second
directed towards the removal or elimination of unwanted substances
(organisms or cells) and the third towards application of a
recombinant vaccine (against tumors or foreign
micro-organisms).
[0008] For the purpose of gene therapy, adenoviruses carrying
deletions have been proposed as suitable vehicles for genetic
information. Adenoviruses are non-enveloped DNA viruses.
Gene-transfer vectors derived from adenoviruses (so-called
"adenoviral vectors") have a number of features that make them
particularly useful for gene transfer for such purposes. For
example, the biology of the adenovirus is characterized in detail,
the adenovirus is not associated with severe human pathology, the
adenovirus is extremely efficient in introducing its DNA into the
host cell, the adenovirus can infect a wide variety of cells and
has a broad host-range, the adenovirus can be produced in large
quantities with relative ease, and the adenovirus can be rendered
replication defective by deletions in the early-region 1 ("E1") of
the viral genome.
[0009] The adenovirus genome is a linear double-stranded DNA
molecule of approximately 36,000 base pairs with the 55 kDa
terminal protein covalently bound to the 5' terminus of each
strand. The adenoviral ("Ad") DNA contains identical Inverted
Terminal Repeats ("ITR") of about 100 base pairs with the exact
length depending on the serotype. The viral origins of replication
are located within the ITRs exactly at the genome ends. DNA
synthesis occurs in two stages. First, the replication proceeds by
strand displacement, generating a daughter duplex molecule and a
parental displaced strand. The displaced strand is single stranded
and can form a so-called "panhandle" intermediate, which allows
replication initiation and generation of a daughter duplex
molecule. Alternatively, replication may proceed from both ends of
the genome simultaneously, obviating the requirement to form the
panhandle structure. The replication is summarized in FIG. 14
adapted from Lechner and Kelly (1977).
[0010] During the productive infection cycle, the viral genes are
expressed in two phases: the early phase, which is the period up to
viral DNA replication, and the late phase, which coincides with the
initiation of viral DNA replication. During the early phase, only
the early gene products, encoded by regions E1, E2, E3 and E4, are
expressed, which carry out a number of functions that prepare the
cell for synthesis of viral structural proteins (Berk, 1986).
During the late phase, the late viral gene products are expressed
in addition to the early gene products, and host cell DNA and
protein synthesis are shut off. Consequently, the cell becomes
dedicated to the production of viral DNA and of viral structural
proteins (Tooze, 1981).
[0011] The E1 region of adenovirus is the first region of
adenovirus expressed after infection of the target cell. This
region consists of two transcriptional units, the E1A and E1B
genes, which both are required for oncogenic transformation of
primary (embryonic) rodent cultures. The main functions of the E1A
gene products are 1) to induce quiescent cells to enter the cell
cycle and resume cellular DNA synthesis and 2) to transcriptionally
activate the E1B gene and the other early regions (E2, E3, E4).
Transfection of primary cells with the E1A gene alone can induce
unlimited proliferation (immortalization) but does not result in
complete transformation. However, expression of E1A in most cases
results in induction of programmed cell death (apoptosis) and only
occasionally immortalization (Jochemsen et al., 1987).
Co-expression of the E1B gene is required to prevent induction of
apoptosis and for complete morphological transformation to occur.
In established immortal cell lines, high level expression of E1A
can cause complete transformation in the absence of E1B (Roberts et
al., 1985).
[0012] The E1B-encoded proteins assist E1A in redirecting the
cellular functions to allow viral replication. The E1B 55 kDa and
E4 33 kDa proteins, which form a complex that is essentially
localized in the nucleus, function in inhibiting the synthesis of
host proteins and in facilitating the expression of viral genes.
Their main influence is to establish selective transport of viral
mRNAs from the nucleus to the cytoplasm concomitantly with the
onset of the late phase of infection. The E1B 21 kDa protein is
important for correct temporal control of the productive infection
cycle, thereby preventing premature death of the host cell before
the virus life cycle has been completed. Mutant viruses incapable
of expressing the E1B 21 kDa gene product exhibit a shortened
infection cycle that is accompanied by excessive degradation of
host cell chromosomal DNA (deg-phenotype) and in an enhanced
cytopathic effect (cyt-phenotype) (Telling et al., 1994). The deg
and cyt phenotypes are suppressed when in addition the E1A gene is
mutated, indicating that these phenotypes are a function of E1A
(White et al., 1988). Furthermore, the E1B 21 kDa protein slows
down the rate by which E1A switches on the other viral genes. It is
not yet known through which mechanisms E1B 21 kDa quenches these
E1A dependent functions.
[0013] Vectors derived from human adenoviruses, in which at least
the E1 region has been deleted and replaced by a gene of interest,
have been used extensively for gene therapy experiments in the
pre-clinical and clinical phase.
[0014] As stated before, all adenovirus vectors currently used in
gene therapy are believed to have a deletion in the E1 region,
where novel genetic information can be introduced. The E1 deletion
renders the recombinant virus replication defective
(Stratford-Perricaudet and Perricaudet, 1991). We have demonstrated
that recombinant adenoviruses are able to efficiently transfer
recombinant genes to the rat liver and airway epithelium of rhesus
monkeys (Bout et al., 1994b; Bout et al., 1994a). In addition, we
(Vincent et al., 1996a; Vincent et al., 1996b) and others (see,
e.g., Haddada et al., 1993) have observed a very efficient in vivo
adenovirus mediated gene transfer to a variety of tumor cells in
vitro and to solid tumors in animals models (lung tumors, glioma)
and human xenografts in immunodeficient mice (lung) in vivo
(reviewed by Blaese et al., 1995).
[0015] In contrast to (for instance) retroviruses, adenoviruses 1)
do not integrate into the host cell genome, 2) are able to infect
non-dividing cells, and 3) are able to efficiently transfer
recombinant genes in vivo (Brody and Crystal, 1994). Those features
make adenoviruses attractive candidates for in vivo gene transfer
of, for instance, suicide or cytokine genes into tumor cells.
[0016] However, a problem associated with current recombinant
adenovirus technology is the possibility of unwanted generation of
replication-competent adenovirus ("RCA") during the production of
recombinant adenovirus (Lochmuller et al., 1994; Imler et al.,
1996). This is caused by homologous recombination between
overlapping sequences from the recombinant vector and the
adenovirus constructs present in the complementing cell line, such
as the 293 cells (Graham et al., 1977). RCA is undesirable in
batches to be used in clinical trials because RCA 1) will replicate
in an uncontrolled fashion, 2) can complement replication-defective
recombinant adenovirus, causing uncontrolled multiplication of the
recombinant adenovirus, and 3) batches containing RCA induce
significant tissue damage and hence strong pathological side
effects (Lochmuller et al., 1994). Therefore, batches to be used in
clinical trials should be proven free of RCA (Ostrove, 1994).
[0017] It was generally thought that E1-deleted vectors would not
express any other adenovirus genes. However, recently it has been
demonstrated that some cell types are able to express adenovirus
genes in the absence of E1 sequences. This indicates that some cell
types possess the machinery to drive transcription of adenovirus
genes. In particular, it was demonstrated that such cells
synthesize E2A and late adenovirus proteins.
[0018] In a gene therapy setting, this means that transfer of the
therapeutic recombinant gene to somatic cells not only results in
expression of the therapeutic protein but may also result in the
synthesis of viral proteins. Cells that express adenoviral proteins
are recognized and killed by Cytotoxic T Lymphocytes, which thus 1)
eradicates the transduced cells and 2) causes inflammations (Bout
et al., 1994a; Engelhardt et al., 1993; Simon et al., 1993). As
this adverse reaction hampers gene therapy, several solutions to
this problem have been suggested, such as 1) using
immunosuppressive agents after treatment, 2) retention of the
adenovirus E3 region in the recombinant vector (see European patent
application EP 95202213), and 3) using temperature-sensitive ("ts")
mutants of human adenovirus, which have a point mutation in the E2A
region rendering them temperature sensitive, as has been claimed in
patent WO/28938.
[0019] However, these strategies to circumvent the immune response
have their limitations. The use of ts mutant recombinant adenovirus
diminishes the immune response to some extent but was less
effective in preventing pathological responses in the lungs
(Engelhardt et al., 1994a).
[0020] The E2A protein may induce an immune response by itself, and
it plays a pivotal role in the switch to the synthesis of late
adenovirus proteins. Therefore, it is attractive to make
temperature-sensitive recombinant human adenoviruses.
[0021] A major drawback of this system is the fact that although
the E2 protein is unstable at the non-permissive temperature, the
immunogenic protein is still being synthesized. In addition, it is
to be expected that the unstable protein does activate late gene
expression, albeit to a low extent. ts125 mutant recombinant
adenoviruses have been tested, and prolonged recombinant gene
expression was reported (Yang et al., 1994b; Engelhardt et al.,
1994a; Engelhardt et al., 1994b; Yang et al., 1995). However,
pathology in the lungs of cotton rats was still high (Engelhardt et
al., 1994a), indicating that the use of ts mutants results in only
a partial improvement in recombinant adenovirus technology. Others
(Fang et al., 1996) did not observe prolonged gene expression in
mice and dogs using ts125 recombinant adenovirus. An additional
difficulty associated with the use of ts125 mutant adenoviruses is
that a high frequency of reversion is observed. These revertants
are either real revertants or the result of second site mutations
(Kruijer et al., 1983; Nicolas et al., 1981). Both types of
revertants have an E2A protein that functions at normal temperature
and, therefore, have toxicity similar to the wild-type virus.
BRIEF SUMMARY OF THE INVENTION
[0022] In one aspect of the invention, this problem in virus
production is solved in that we have developed packaging cells that
have no overlapping sequences with a new basic vector and thus are
suited for safe large scale production of recombinant adenoviruses.
One of the additional problems associated with the use of
recombinant adenovirus vectors is the host-defense reaction against
treatment with adenovirus.
[0023] Briefly, recombinant adenoviruses are deleted for the E1
region. The adenovirus E1 products trigger the transcription of the
other early genes (E2, E3, E4), which consequently activate
expression of the late virus genes.
[0024] In another aspect of the present invention, we therefore
delete E2A coding sequences from the recombinant adenovirus genome
and transfect these E2A sequences into the (packaging) cell lines
containing E1 sequences to complement recombinant adenovirus
vectors.
[0025] Major hurdles in this approach are 1) that E2A should be
expressed to very high levels and 2) that E2A protein is very toxic
to cells.
[0026] The current invention, in yet another aspect, therefore
discloses use of the ts125 mutant E2A gene, which produces a
protein that is not able to bind DNA sequences at the
non-permissive temperature. High levels of this protein may be
maintained in the cells (because it is non-toxic at this
temperature) until the switch to the permissive temperature is
made. This can be combined with placing the mutant E2A gene under
the direction of an inducible promoter, such as, for instance, tet,
methallothionein, steroid inducible promoter, retinoic acid
.beta.-receptor, or other inducible systems. However, in yet
another aspect of the invention, the use of an inducible promoter
to control the moment of production of toxic wild-type E2A is
disclosed.
[0027] Two salient additional advantages of E2A-deleted recombinant
adenovirus are 1) the increased capacity to harbor heterologous
sequences and 2) the permanent selection for cells that express the
mutant E2A. This second advantage relates to the high frequency of
reversion of ts125 mutation: when reversion occurs in a cell line
harboring ts125 E2A, this will be lethal to the cell. Therefore,
there is a permanent selection for those cells that express the
ts125 mutant E2A protein. In addition, as we in one aspect of the
invention generate E2A-deleted recombinant adenovirus, we will not
have the problem of reversion in our adenoviruses.
[0028] In yet another aspect of the invention, as a further
improvement, the use of non-human cell lines as packaging cell
lines is disclosed.
[0029] For GMP production of clinical batches of recombinant
viruses, it is desirable to use a cell line that has been used
widely for production of other biotechnology products. Most of the
latter cell lines are of monkey origin, which have been used to
produce, for example, vaccines.
[0030] These cells can not be used directly for the production of
recombinant human adenovirus, as human adenovirus cannot replicate
or replicates only to low levels in cells of monkey origin. A block
in the switch of early to late phase of adenovirus lytic cycle
underlies defective replication. However, host range mutations in
the human adenovirus genome are described (hr 400-404), which allow
replication of human viruses in monkey cells. These mutations
reside in the gene encoding E2A protein (Klessig and Grodzicker,
1979; Klessig et al., 1984; Rice and Klessig, 1985; Klessig et al.,
1984). Moreover, mutant viruses have been described that harbor
both the hr and temperature-sensitive ts125 phenotype (Brough et
al., 1985; Rice and Klessig, 1985).
[0031] We, therefore, generate packaging cell lines of monkey
origin (e.g., VERO, CV1) that harbor: [0032] 1) E1 sequences, to
allow replication of E1/E2-defective adenoviruses, and [0033] 2)
E2A sequences, containing the hr mutation and the ts125 mutation,
named ts400 (Brough et al., 1985; Rice and Klessig, 1985) to
prevent cell death by E2A overexpression, and/or [0034] 3) E2A
sequences, just containing the hr mutation, under the control of an
inducible promoter, and/or [0035] 4) E2A sequences, containing the
hr mutation and the ts125 mutation (ts400), under the control of an
inducible promoter.
[0036] Furthermore we disclose the construction of novel and
improved combinations of packaging cell lines and recombinant
adenovirus vectors. We provide: [0037] 1) A novel packaging cell
line derived from diploid human embryonic retinoblasts ("HER") that
harbors nt. 80-5788 of the Ad5 genome. This cell line, named 911,
deposited under no. 95062101 at the ECACC.TM., has many
characteristics that make it superior to the commonly used 293
cells (Fallaux et al., 1996); [0038] 2) Novel packaging cell lines
that express just E1A genes and not E1B genes. Established cell
lines (and not human diploid cells of which 293 and 911 cells are
derived) are able to express E1A to high levels without undergoing
apoptotic cell death, as occurs in human diploid cells that express
E1A in the absence of E1B. Such cell lines are able to
trans-complement E1B-defective recombinant adenoviruses, because
viruses mutated for E1B 21 kDa protein are able to complete viral
replication even faster than wild-type adenoviruses (Telling et
al., 1994). The constructs are described in detail below and are
graphically represented in FIGS. 1-5. The constructs are
transfected into the different established cell lines and are
selected for high expression of E1A. This is done by operatively
linking a selectable marker gene (e.g., NEO gene) directly to the
E1B promoter. The E1B promoter is transcriptionally activated by
the E1A gene product, and, therefore, resistance to the selective
agent (e.g., G418 in the case of NEO is used as the selection
marker) results in direct selection for desired expression of the
E1A gene; [0039] 3) Packaging constructs that are mutated or
deleted for E1B 21 kDa, but just express the 55 kDa protein; [0040]
4) Packaging constructs to be used for generation of complementing
packaging cell lines from diploid cells (not exclusively of human
origin) without the need for selection with marker genes. These
cells are immortalized by expression of E1A. However, in this
particular case, expression of E1B is essential to prevent
apoptosis induced by E1A proteins. Selection of E1-expressing cells
is achieved by selection for focus formation (immortalization), as
described for 293 cells (Graham et al., 1977) and 911 cells
(Fallaux et al., 1996), that are E1-transformed human embryonic
kidney ("HEK") cells and human embryonic retinoblasts ("HER"),
respectively; [0041] 5) After transfection of HER cells with
construct pIG.E1B (see FIG. 4), seven independent cell lines could
be established. These cell lines were designated PER.C1, PER.C3,
PER.C4, PER.C5, PER.C6.TM., PER.C8, and PER.C9. PER denotes
PGK-E1-Retinoblasts. These cell lines express E1A and E1B proteins,
are stable (e.g., PER.C6.TM. for more than 57 passages), and
complement E1-defective adenovirus vectors. Yields of recombinant
adenovirus obtained on PER cells are a little higher than obtained
on 293 cells. One of these cell lines (PER.C6.TM.) has been
deposited at the ECACC.TM. under number 96022940; [0042] 6) New
adenovirus vectors with extended E1 deletions (deletion nt.
459-3510). Those viral vectors lack sequences homologous to E1
sequences in said packaging cell lines. These adenoviral vectors
contain pIX promoter sequences and the pIX gene, as pIX (from its
natural promoter sequences) can only be expressed from the vector
and not by packaging cells (Matsui et al., 1986, Hoeben and
Fallaux, personal communication; Imler et al., 1996); [0043] 7)
E2A-expressing packaging cell lines preferably based on either
E1A-expressing established cell lines or E1A-E1B-expressing diploid
cells (see under 2-4). E2A expression is either under the control
of an inducible promoter or the E2A ts125 mutant is driven by
either an inducible or a constitutive promoter. [0044] 8)
Recombinant adenovirus vectors as described before (see 6) but
carrying an additional deletion of E2A sequences; [0045] 9)
Adenovirus packaging cells from monkey origin that are able to
trans-complement E1-defective recombinant adenoviruses. They are
preferably co-transfected with pIG.E1A.E1B and pIG.NEO and selected
for NEO resistance. Such cells expressing E1A and E1B are able to
transcomplement E1-defective recombinant human adenoviruses but
will do so inefficiently because of a block of the synthesis of
late adenovirus proteins in cells of monkey origin (Klessig and
Grodzicker, 1979). To overcome this problem, we generate
recombinant adenoviruses that harbor a host-range mutation in the
E2A gene, allowing human adenoviruses to replicate in monkey cells.
Such viruses are generated as described in FIG. 12, except DNA from
an hr-mutant is used for homologous recombination; and [0046] 10)
Adenovirus packaging cells from monkey origin as described under 9,
except that they will also be co-transfected with E2A sequences
harboring the hr mutation. This allows replication of human
adenoviruses lacking E1 and E2A (see under 8). E2A in these cell
lines is either under the control of an inducible promoter or the
tsE2A mutant is used. In the latter case, the E2A gene will thus
carry both the ts mutation and the hr mutation (derived from
ts400). Replication-competent human adenoviruses have been
described that harbor both mutations (Brough et al., 1985; Rice and
Klessig, 1985).
[0047] A further aspect of the invention provides otherwise
improved adenovirus vectors, as well as novel strategies for
generation and application of such vectors and a method for the
intracellular amplification of linear DNA fragments in mammalian
cells.
BRIEF DESCRIPTION OF THE DRAWINGS
[0048] The following figures and drawings may help to understand
the invention:
[0049] FIG. 1 illustrates the construction of pBS.PGK.PCR1;
[0050] FIG. 2 illustrates the construction of pIG.E1A.E1B.X;
[0051] FIGS. 3A and 3B illustrate the construction of
pIG.E1A.NEO;
[0052] FIG. 4 illustrates the construction of pIG.E1A.E1B;
[0053] FIG. 5 illustrates the construction of pIG.NEO;
[0054] FIG. 6 illustrates the transformation of primary baby rat
kidney ("BRK") cells by adenovirus packaging constructs;
[0055] FIG. 7 illustrates a Western blot analysis of A549 clones
transfected with pIG.E1A.NEO and HER cells transfected with
pIG.E1A.E1B (PER clones);
[0056] FIG. 8 illustrates a Southern blot analysis of 293, 911 and
PER cell lines. Cellular DNA was extracted, HindIII digested,
electrophoresed and transferred to Hybond N+membranes
(Amersham);
[0057] FIG. 9 illustrates the transfection efficiency of PER.C3,
PER.C5, PER.C6.TM. and 911 cells;
[0058] FIG. 10 illustrates construction of adenovirus vector
pMLPI.TK. pMLPI.TK designed to have no sequence overlap with the
packaging construct pIG.E1A.E1B;
[0059] FIGS. 11A and 11B illustrate new adenovirus packaging
constructs which do not have sequence overlap with new adenovirus
vectors;
[0060] FIG. 12 illustrate the generation of recombinant adenovirus
IG.Ad.MLPI.TK;
[0061] FIG. 13 illustrates the adenovirus double-stranded DNA
genome indicating the approximate locations of E1, E2, E3, E4, and
L regions;
[0062] FIG. 14 illustrates the adenovirus genome is shown in the
top left with the origins of replication located within the left
and right ITRs at the genome ends.
[0063] FIG. 15 illustrates a potential hairpin conformation of a
single-stranded DNA molecule that contains the HP/asp sequence (SEQ
ID NO:22 of the incorporated hereby SEQUENCE LISTING);
[0064] FIG. 16 illustrates a diagram of pICLhac;
[0065] FIG. 17 illustrates a diagram of pICLhaw;
[0066] FIG. 18 illustrates a schematic representation of pICLI;
[0067] FIG. 19 is a diagram of pICL (SEQ ID NO:21); and
[0068] FIGS. 20A-20F recite the nucleotide sequence of pICL 5620BPS
DNA (circular) (SEQ ID NO:21).
DETAILED DESCRIPTION OF THE INVENTION
[0069] The so-called "minimal" adenovirus vectors according to the
present invention retain at least a portion of the viral genome
that is required for encapsidation of the genome into virus
particles (the encapsidation signal), as well as at least one copy
of at least a functional part or a derivative of the ITR, that is
DNA sequences derived from the termini of the linear adenovirus
genome. The vectors according to the present invention will also
contain a transgene linked to a promoter sequence to govern
expression of the transgene. Packaging of the so-called minimal
adenovirus vector can be achieved by co-infection with a helper
virus or, alternatively, with a packaging deficient replicating
helper system, as described below.
[0070] Adenovirus-derived DNA fragments that can replicate in
suitable cell lines and that may serve as a packaging deficient
replicating helper system are generated as follows. These DNA
fragments retain at least a portion of the transcribed region of
the "late" transcription unit of the adenovirus genome and carry
deletions in at least a portion of the E1 region and deletions in
at least a portion of the encapsidation signal. In addition, these
DNA fragments contain at least one copy of an ITR. At one terminus
of the transfected DNA molecule an ITR is located. The other end
may contain an ITR, or alternatively, a DNA sequence that is
complementary to a portion of the same strand of the DNA molecule
other than the ITR. If, in the latter case, the two complementary
sequences anneal, the free 3'-hydroxyl group of the 3' terminal
nucleotide of the hairpin-structure can serve as a primer for DNA
synthesis by cellular and/or adenovirus-encoded DNA polymerases,
resulting in conversion into a double-stranded form of at least a
portion of the DNA molecule. Further replication initiating at the
ITR will result in a linear double-stranded DNA molecule that is
flanked by two ITRs and is larger than the original transfected DNA
molecule (see FIG. 13). This molecule can replicate itself in the
transfected cell by virtue of the adenovirus proteins encoded by
the DNA molecule and the adenoviral and cellular proteins encoded
by genes in the host-cell genome. This DNA molecule can not be
encapsidated due to its large size (greater than 39,000 base pairs)
or due to the absence of a functional encapsidation signal. This
DNA molecule is intended to serve as a helper for the production of
defective adenovirus vectors in suitable cell lines.
[0071] The invention also comprises a method for amplifying linear
DNA fragments of variable size in suitable mammalian cells. These
DNA fragments contain at least one copy of the ITR at one of the
termini of the fragment. The other end may contain an ITR, or
alternatively, a DNA sequence that is complementary to a portion of
the same strand of the DNA molecule other than the ITR. If, in the
latter case, the two complementary sequences anneal, the free
3'-hydroxyl group of the 3' terminal nucleotide of the hairpin
structure can serve as a primer for DNA synthesis by cellular
and/or adenovirus-encoded DNA polymerases, resulting in conversion
of the displaced strand into a double stranded form of at least a
portion of the DNA molecule. Further replication initiating at the
ITR will result in a linear double-stranded DNA molecule that is
flanked by two ITRs, which is larger than the original transfected
DNA molecule. A DNA molecule that contains ITR sequences at both
ends can replicate itself in transfected cells by virtue of the
presence of at least the adenovirus E2 proteins (viz. the
DNA-binding protein ("DBP"), the adenovirus DNA polymerase
("Ad-pol"), and the pre-terminal protein ("pTP"). The required
proteins may be expressed from adenovirus genes on the DNA molecule
itself, from adenovirus E2 genes integrated in the host-cell
genome, or from a replicating helper fragment, as described
above.
[0072] Several groups have shown that the presence of ITR sequences
at the end of DNA molecules are sufficient to generate adenovirus
minichromosomes that can replicate, if the adenovirus-proteins
required for replication are provided in trans, for example, by
infection with a helper virus (Hu et al., 1992; Wang and Pearson,
1985; Hay et al., 1984). Hu et al. (1992) observed the presence and
replication of symmetrical adenovirus minichromosome dimers after
transfection of plasmids containing a single ITR. The authors were
able to demonstrate that these dimeric minichromosomes arise after
tail-to-tail ligation of the single ITR DNA molecules. In DNA
extracted from defective adenovirus type 2 particles, dimeric
molecules of various sizes have also been observed using
electron-microscopy (Daniell, 1976). It was suggested that the
incomplete genomes were formed by illegitimate recombination
between different molecules and that variations in the position of
the sequence at which the illegitimate base pairing occurred were
responsible for the heterogeneous nature of the incomplete genomes.
Based on this mechanism it was speculated that, in theory,
defective molecules with a total length of up to two times the
normal genome could be generated. Such molecules could contain
duplicated sequences from either end of the genome. However, no DNA
molecules larger than the full-length virus were found packaged in
the defective particles (Daniell, 1976). This can be explained by
the size limitations that apply to the packaging. In addition, it
was observed that in the virus particles, DNA molecules with a
duplicated left-end predominated over those containing the
right-end terminus (Daniell, 1976). This is fully explained by the
presence of the encapsidation signal near that left-end of the
genome (Grable and Hearing, 1990; Grable and Hearing, 1992; Hearing
et al., 1987).
[0073] The major problems associated with the current
adenovirus-derived vectors are: [0074] 1) The strong immunogenicity
of the virus particle; [0075] 2) The expression of adenovirus genes
that reside in the adenoviral vectors, resulting in a Cytotoxic
T-cell response against the transduced cells; and [0076] 3) The low
amount of heterologous sequences that can be accommodated in the
current vectors (up to maximally approximately 8000 base pairs
("bp") of heterologous DNA).
[0077] The strong immunogenicity of the adenovirus particle results
in an immunological response of the host, even after a single
administration of the adenoviral vector. As a result of the
development of neutralizing antibodies, a subsequent administration
of the virus will be less effective or even completely ineffective.
However, a prolonged or persistent expression of the transferred
genes will reduce the number of administrations required and may
bypass the problem.
[0078] With regard to problem 2), experiments performed by Wilson
and collaborators have demonstrated that after adenovirus-mediated
gene transfer into immunocompetent animals, the expression of the
transgene gradually decreases and disappears approximately two to
four weeks post-infection (Yang et al. 1994a; Yang et al., 1994b).
This is caused by the development of a Cytotoxic T-Cell ("CTL")
response against the transduced cells. The CTLs were directed
against adenovirus proteins expressed by the viral vectors. In the
transduced cells, synthesis of the adenovirus DNA-binding protein
(the E2A-gene product), penton, and fiber proteins (late-gene
products) could be established. These adenovirus proteins, encoded
by the viral vector, were expressed despite deletion of the E1
region. This demonstrates that deletion of the E1 region is not
sufficient to completely prevent expression of the viral genes
(Engelhardt et al., 1994a).
[0079] With regard to problem 3), studies by Graham and
collaborators have demonstrated that adenoviruses are capable of
encapsidating DNA of up to 105% of the normal genome size (Bett et
al., 1993). Larger genomes tend to be unstable, resulting in loss
of DNA sequences during propagation of the virus. Combining
deletions in the E1 and E3 regions of the viral genomes increases
the maximum size of the foreign DNA that can be encapsidated to
approximately 8.3 kb. In addition, some sequences of the E4 region
appear to be dispensable for virus growth (adding another 1.8 kb to
the maximum encapsidation capacity). Also, the E2A region can be
deleted from the vector when the E2A gene product is provided in
trans in the encapsidation cell line, adding another 1.6 kb. It is,
however, unlikely that the maximum capacity of foreign DNA can be
significantly increased further than 12 kb.
[0080] We developed a new strategy for the generation and
production of helper-free-stocks of recombinant adenovirus vectors
that can accommodate up to 38 kb of foreign DNA. Only two
functional ITR sequences and sequences that can function as an
encapsidation signal need to be part of the vector genome. Such
vectors are called "minimal adenovectors." The helper functions for
the minimal adenovectors are provided in trans by
encapsidation-defective replication-competent DNA molecules that
contain all the viral genes encoding the required gene products,
with the exception of those genes that are present in the host-cell
genome, or genes that reside in the vector genome.
[0081] The applications of the disclosed inventions are outlined
below and will be illustrated in the experimental part, which is
only intended for that purpose and should not be used to reduce the
scope of the present invention as understood by those skilled in
the art.
Use of the IG Packaging Constructs Diploid Cells
[0082] The constructs, in particular pIG.E1A.E1B, will be used to
transfect diploid human cells, such as HER, HEK, and Human
Embryonic Lung cells ("HEL"). Transfected cells will be selected
for transformed phenotype (focus formation) and tested for their
ability to support propagation of E1-deleted recombinant
adenovirus, such as IG.Ad.MLPI.TK. Such cell lines will be used for
the generation and (large-scale) production of E1-deleted
recombinant adenoviruses. Such cells, infected with recombinant
adenovirus, are also intended to be used in vivo as a local
producer of recombinant adenovirus, for example, for the treatment
of solid tumors.
[0083] 911 cells are used for the titration, generation, and
production of recombinant adenovirus vectors (Fallaux et al.,
1996).
[0084] HER cells transfected with pIG.E1A.E1B have resulted in
seven independent clones (called PER cells). These clones are used
for the production of E1-deleted (including non-overlapping
adenovirus vectors) or E1-defective recombinant adenovirus vectors
and provide the basis for introduction of, for example, E2B or E2A
constructs (e.g., ts125E2A, see below), E4 etc., that will allow
propagation of adenovirus vectors that have mutations in, for
example, E2A or E4.
[0085] In addition, diploid cells of other species that are
permissive for human adenovirus, such as the cotton rat (Sigmodon
hispidus) (Pacini et al., 1984), Syrian hamster (Morin et al.,
1987), or chimpanzee (Levrero et al., 1991), will be immortalized
with these constructs. Such cells infected with recombinant
adenovirus are also intended to be used in vivo for the local
production of recombinant adenovirus, for example, for the
treatment of solid tumors.
Established Cells
[0086] The constructs, in particular pIG.E1A.NEO, can be used to
transfect established cells, for example, A549 (human bronchial
carcinoma), KB (oral carcinoma), MRC-5 (human diploid lung cell
line), or GLC cell lines (small cell lung cancer) (de Leij et al.,
1985; Postmus et al., 1988) and selected for NEO resistance.
Individual colonies of resistant cells are isolated and tested for
their capacity to support propagation of E1-deleted recombinant
adenovirus, such as IG.Ad.MLPI.TK. When propagation of E1-deleted
viruses on E1A containing cells is possible, such cells can be used
for the generation and production of E1-deleted recombinant
adenovirus. They can also be used for the propagation of
E1A-deleted/E1B-retained recombinant adenovirus.
[0087] Established cells can also be co-transfected with
pIG.E1A.E1B and pIG.NEO (or another NEO containing expression
vector). Clones resistant to G418 are tested for their ability to
support propagation of E1-deleted recombinant adenovirus, such as
IG.Ad.MLPI.TK, and used for the generation and production of
E1-deleted recombinant adenovirus and will be applied in vivo for
local production of recombinant virus, as described for the diploid
cells (see previous discussion). All cell lines, including
transformed diploid cell lines or NEO-resistant established lines,
can be used as the basis for the generation of "next generation"
packaging cell lines that support propagation of E1-defective
recombinant adenoviruses and that also carry deletions in other
genes, such as E2A and E4. Moreover, they will provide the basis
for the generation of minimal adenovirus vectors as disclosed
herein.
E2-Expressing Cell Lines
[0088] Packaging cells expressing E2A sequences are and will be
used for the generation and large scale production of E2A-deleted
recombinant adenovirus.
[0089] The newly generated human adenovirus packaging cell lines or
cell lines derived from species permissive for human adenovirus
(E2A or ts125E2A: E1A+E2A; E1A+E1B+E2A; E1A-E2A/ts125;
E1A+E1B-E2A/ts125) or non-permissive cell lines such as monkey
cells (hrE2A or hr+ts125E2A; E1A+hrE2A; E1A+E1B+hrE2A;
E1A+hrE2A/ts125; E1A-E1B+hrE2A/ts125) are and will be used for the
generation and large scale production of E2A-deleted recombinant
adenovirus vectors. In addition, they will be applied in vivo for
local production of recombinant virus, as described for the diploid
cells (see previous discussion).
Novel Adenovirus Vectors
[0090] The newly developed adenovirus vectors harboring an E1
deletion of nt. 459-3510 will be used for gene transfer purposes.
These vectors are also the basis for the development of further
deleted adenovirus vectors that are mutated for, for example, E2A,
E2B or E4. Such vectors will be generated, for example, on the
newly developed packaging cell lines described above.
Minimal Adenovirus Packaging System
[0091] We disclose adenovirus packaging constructs (to be used for
the packaging of minimal adenovirus vectors) which have the
following characteristics: [0092] 1) the packaging construct
replicates; [0093] 2) the packaging construct can not be packaged
because the packaging signal is deleted; [0094] 3) the packaging
construct contains an internal hairpin-forming sequence (see FIG.
15); [0095] 4) because of the internal hairpin structure, the
packaging construct is duplicated, that is, the DNA of the
packaging construct becomes twice as long as it was before
transfection into the packaging cell (in our sample, it duplicates
from 35 kb to 70 kb). This duplication also prevents packaging.
Note that this duplicated DNA molecule has ITRs at both termini
(see, e.g., FIG. 13); [0096] 5) this duplicated packaging molecule
is able to replicate like a "normal adenovirus" DNA molecule;
[0097] 6) the duplication of the genome is a prerequisite for the
production of sufficient levels of adenovirus proteins required to
package the minimal adenovirus vector; and [0098] 7) the packaging
construct has no overlapping sequences with the minimal vector or
cellular sequences that may lead to generation of RCA by homologous
recombination.
[0099] This packaging system is used to produce minimal adenovirus
vectors. The advantages of minimal adenovirus vectors, for example,
for gene therapy of vaccination purposes, are well known
(accommodation of up to 38 kb; gutting of potentially toxic and
immunogenic adenovirus genes).
[0100] Adenovirus vectors containing mutations in essential genes
(including minimal adenovirus vectors) can also be propagated using
this system.
Use of Intracellular E2-Expressing Vectors
[0101] Minimal adenovirus vectors are generated using the helper
functions provided in trans by packaging-deficient replicating
helper molecules. The adenovirus-derived ITR sequences serve as
origins of DNA replication in the presence of at least the E2 gene
products. When the E2 gene products are expressed from genes in the
vector genome (the gene(s) must be driven by an E1-independent
promoter), the vector genome can replicate in the target cells.
This will allow a significantly increased number of template
molecules in the target cells, and, as a result, an increased
expression of the genes of interest encoded by the vector. This is
of particular interest for application of gene therapy in cancer
treatment.
Applications of Intracellular Amplification of Linear DNA
Fragments
[0102] A similar approach could also be taken if amplification of
linear DNA fragments is desired. DNA fragments of known or unknown
sequence could be amplified in cells containing the E2 gene
products if at least one ITR sequence is located near or at its
terminus. There are no apparent constraints on the size of the
fragment. Even fragments much larger than the adenovirus genome (36
kb) should be amplified using this approach. It is thus possible to
clone large fragments in mammalian cells without either shuttling
the fragment into bacteria (such as E. coli) or using the
polymerase chain reaction ("PCR"). At the end stage of a productive
adenovirus infection, a single cell can contain over 100,000 copies
of the viral genome. In the optimal situation, the Linear DNA
fragments can be amplified to similar levels. Thus, one should be
able to extract more than 5 .mu.g of DNA fragment per 10 million
cells (for a 35-kbp fragment). This system can be used to express
heterologous proteins equivalent to the Simian Virus 40-based COS
cell system for research or for therapeutic purposes. In addition,
the system can be used to identify genes in large fragments of DNA.
Random DNA fragments may be amplified (after addition of ITRs) and
expressed during intracellular amplification. Election or selection
of those cells with the desired phenotype can be used to enrich the
fragment of interest and to isolate the gene.
EXPERIMENTS
Generation of Cell Lines Able to Transcomplement E1-Defective
Recombinant Adenovirus Vectors
[0103] 911 Cell Line
[0104] We have generated a cell line that harbors E1 sequences of
adenovirus type 5 ("Ad5"), able to trans-complement E1-deleted
recombinant adenovirus (Fallaux et al., 1996). This cell line was
obtained by transfection of human diploid human embryonic
retinoblasts ("HER") with pAd5XhoIC, which contains nt. 80-5788 of
Ad5. One of the resulting transformants was designated 911. This
cell line has been shown to be very useful in the propagation of
E1-defective recombinant adenovirus. It was found to be superior to
293 cells. Unlike 293 cells, 911 cells lack a fully transformed
phenotype, which most likely is the cause of its better performance
as an adenovirus packaging line: [0105] 1) plaque assays can be
performed faster (four to five days instead of eight to fourteen
days, as on 293), [0106] 2) monolayers of 911 cells survive better
under agar overlay, as required for plaque assays, and [0107] 3)
higher amplification of E1-deleted vectors is obtained.
[0108] In addition, unlike 293 cells that were transfected with
sheared adenoviral DNA, 911 cells were transfected using a defined
construct. Transfection efficiencies of 911 cells are comparable to
those of 293.
New Packaging Constructs. Source of Adenovirus Sequences
[0109] Adenovirus sequences are derived either from pAd5.SalB,
containing nt. 80-9460 of human adenovirus type 5 (Bernards et al.,
1983), or from wild-type Ad5 DNA. pAd5.SalB was digested with SalI
and XhoI, the large fragment was relegated, and this new clone was
named pAd5.X/S. The pTN construct (constructed by Dr. R. Vogels,
IntroGene, Leiden, The Netherlands) was used as a source for the
human PGK promoter and the NEO gene.
Human PGK Promoter and NEO.sup.R Gene
[0110] Transcription of E1A sequences in the new packaging
constructs is driven by the human PGK promoter (Michelson et al.,
1983; Singer-Sam et al., 1984), derived from plasmid pTN (gift of
R. Vogels), which uses pUC119 (Vieira and Messing, 1987) as a
backbone. This plasmid was also used as a source for NEO gene fused
to the Hepatitis B Virus ("HBV") poly-adenylation signal.
Fusion of PGK Promoter to E1 Genes
[0111] As shown in FIG. 1, in order to replace the E1 sequences of
Ad5 (ITR, origin of replication, and packaging signal) by
heterologous sequences we have amplified E1 sequences (nt. 459 to
nt. 960) of Ad5 by PCR, using primers Ea-1 (SEQ ID NO: 1) and Ea-2
(SEQ ID NO:2) (see Table I). The resulting PCR product was digested
with ClaI and ligated into Bluescript (Stratagene), predigested
with ClaI and EcoRV, resulting in construct pBS.PCR1.
TABLE-US-00001 TABLE I Name (SEQ ID NO) Sequence Function Primer
Ea-1 CGTGTAGTGT ATTTATACCCG PCR amplification Ad5 (SEQ ID NO: 1) a
nt 459 -> Primer Ea-2 TCGTCACTGG GTGGAAAGCCA PCR amplification
Ad5 (SEQ ID NO: 2) a nt 960 <- Primer Ea-3 TACCCGCCGT
CCTAAAATGGC nt 1284-1304 of Ad5 (SEQ ID NO: 3) a genome Primer Ea-5
TGGACTTGAG CTGTAAACGC nt 1514-1533 of Ad5 (SEQ ID NO: 4) a genome
Primer Ep-2 GCCTCCATGG AGGTCAGATGT nt 1721-1702 of Ad5: (SEQ ID NO:
5) a introduction of NcoI site Primer Eb-1 GCTTGAGCCC GAGACATGTC nt
3269-3289 of Ad5 (SEQ ID NO: 6) a genome Primer Eb-2 CCCCTCGAGC
TCAATCTGTATCTT nt 3508-3496 of Ad5 (SEQ ID NO: 7) a genome:
introduction of XhoI site Primer SV40-1 GGGGGATCCG AACTTGTTTA
Introduction BamHI site (SEQ ID NO: 8) a TTGCAGC (nt 2182-2199 of
pMLP.TK) adaption of recombinant adenoviruses Primer SV40-2
GGGAGATCTA GACATGATAA Introduction BglII site (SEQ ID NO: 9) a
GATAC (nt 2312-2297 of pMLP.TK) Primer Ad5-1 GGGAGATCTG TACTGAAATG
Introduction of BglII (SEQ ID NO: 10) a TGTGGGC site (nt 2496-2514
of pMLP.TK) Primer Ad5-2 GGAGGCTGCA GTCTCCAACGGCGT Rnt 2779-2756 of
(SEQ ID NO: 11) a PMLP.TK Primer ITR1 GGGGGATCCT CAAATCGTCA nt
35737-35757 of Ad5 (SEQ ID NO: 12) a CTTCCGT (introduction of BamHI
site) Primer ITR2 GGGGTCTAGA CATCATCAAT nt 35935-35919 of Ad5 (SEQ
ID NO: 13 a AATATAC (introduction of XbaI site) PCR primer PCR/MLP1
GGCGAATTCG TCGACATCAT (Ad5 nt. 10-18) (SEQ ID NO: 14) b CAATAATATA
CC PCT primer PCR/MLP2 GGCGAATTCG GTACCATCAT (Ad5 nt. 10-18) (SEQ
ID NO: 15) b CAATAATATA CC PCT primer PCR/MLP3 CTGTGTACAC CGGCGCA
(Ad5 nt. 200-184) (SEQ ID NO: 16) b PCT primer HP/asp1
5'-GTACACTGAC CTAGTGCCGC (SEQ ID NO: 17) c CCGGGCAAAG CCCGGGCGGC
ACTAGGTCAG PCT primer HP/asp2 5'-GTACCTGACC TAGTGCCGCC (SEQ ID NO:
18) c CGGGCTTTGC CCGGGCGGCA CTAGGTCAGT PCT primer HP/cla1
5'-GTACATTGAC CTAGTGCCGC (SEQ ID NO: 19) d CCGGGCAAAG CCCGGGCGGC
ACTAGGTCAA TCGAT PCT primer HP/cla2 5'-GTACATCGAT TGACCTAGTG (SEQ
ID NO: 20) d CCGCCCGGGC TTTGCCCGGG CGGCACTAGG TCAAT
[0112] Table I. Primer Sequences. [0113] a--Primers used for PCR
amplification of DNA fragments used for generation of constructs
described in this patent application. [0114] b--PCR primers sets to
be used to create the SalI and Asp718 sites juxtaposed to the ITR
sequences. [0115] c--Synthetic oligonucleotide pair used to
generate a synthetic hairpin, recreates an Asp718 site at one of
the termini if inserted in Asp718 site. [0116] d--Synthetic
oligonucleotide pair used to generate a synthetic hairpin, contains
the ClaI recognition site to be used for hairpin formation.
[0117] Vector pTN was digested with restriction enzymes EcoRI
(partially) and ScaI and the DNA fragment containing the PGK
promoter sequences was ligated into PBS.PCR1 digested with ScaI and
EcoRI. The resulting construct pBS.PGK.PCR1 contains the human PGK
promoter operatively linked to Ad5 E1 sequences from nt. 459 to nt.
916.
Construction of pIG.E1A.E1B.X
[0118] As shown in FIG. 2, pIG.E1A.E1B.X was made by replacing the
ScaI-BspEI fragment of pAT.X/S by the corresponding fragment from
pBS.PGK.PCR1 (containing the PGK promoter linked to E1A sequences).
pIG.E1A.E1B.X contains the E1A and E1B coding sequences under the
direction of the PGK promoter. As Ad5 sequences from nt. 459 to nt.
5788 are present in this construct, pIX protein of adenovirus is
also encoded by this plasmid.
Construction of pIG.E1A.NEO
[0119] As shown in FIG. 3A, in order to introduce the complete E1B
promoter and to fuse this promoter in such a way that the AUG codon
of E1B 21 kDa exactly functions as the AUG codon of NEO.sup.R, we
amplified the E1B promoter using primers Ea-3 (SEQ ID NO:3) and
Ep-2 (SEQ ID NO:5), where primer Ep-2 (SEQ ID NO:5) introduces an
NcoI site in the PCR fragment. The resulting PCR fragment, named
PCRII, was digested with HpaI and NcoI and ligated into pAT-X/S,
which was predigested with HpaI and with NcoI. The resulting
plasmid was designated pAT.X/S.PCR2. The NcoI-StuI fragment of pTN,
containing the NEO gene and part of the HBV poly-adenylation
signal, was cloned into pAT.X/S.PCR2 (digested with NcoI and NruI).
The resulting construct: pAT.PCR2.NEO.
[0120] As shown in FIG. 3B, the poly-adenylation signal was
completed by replacing the ScaI-SalI fragment of pAT-PCR2-NEO with
the corresponding fragment of pTN (resulting in pAT.PCR2.NEO.p(A)).
The ScaI-XbaI of pAT.PCR2.NEO.p (A) was replaced by the
corresponding fragment of pIG.E1A.E1B-X, containing the PGK
promoter linked to E1A genes. The resulting construct was named
pIG.E1A.NEO, and thus contains Ad5 E1 sequences (nt. 459 to nt.
1713) under the control of the human PGK promoter.
Construction of pIG.EIA.E1B
[0121] As shown in FIG. 4, pIG.E1A.E1B was made by amplifying the
sequences encoding the N-terminal amino acids of E1B 55 kDa using
primers Eb-1 (SEQ ID NO:6) and Eb-2 (SEQ ID NO:7) (introduces an
XhoI site). The resulting PCR fragment was digested with BglII and
cloned into BglII/NruI of pAT-X/S, thereby obtaining pAT.PCR3.
[0122] pIG.E1A.E1B was constructed by introducing the HBV poly(A)
sequences of pIG.E1A.NEO downstream of E1B sequences of pAT.PCR3 by
exchange of XbaI-SalI fragment of pIG.E1A.NEO and the XbaI XhoI
fragment of pAT.PCR3.
[0123] pIG.E1A.E1B contains nt. 459 to nt. 3510 of Ad5, which
encode the E1A and E1B proteins. The E1B sequences are terminated
at the splice acceptor at nt. 3511. No pIX sequences are present in
this construct.
Construction of pIG.NEO
[0124] As shown in FIG. 5, pIG.NEO was generated by cloning the
HpaI-ScaI fragment of pIG.E1A.NEO, containing the NEO gene under
the control of the Ad.5 E1B promoter, into pBS digested with EcoRV
and ScaI.
[0125] This construct is of use when established cells are
transfected with E1A.E1B constructs and NEO selection is required.
Because NEO expression is directed by the E1B promoter,
NEO-resistant cells are expected to co-express E1A, which is also
advantageous for maintaining high levels of expression of E1A
during long-term culture of the cells.
Testing of Constructs
[0126] The integrity of the constructs pIG.E1A.NEO, pIG.E1A.E1B.X
and pIG.E1A.E1B was assessed by restriction enzyme mapping;
furthermore, parts of the constructs that were obtained by PCR
analysis were confirmed by sequence analysis. No changes in the
nucleotide sequence were found.
[0127] The constructs were transfected into primary Baby Rat Kidney
("BRK") cells and tested for their ability to immortalize
(pIG.E1A.NEC) or fully transform (pAd5.XhoIC, pIG.E1A.E1B.X, and
pIG.E1A.E1B) these cells.
[0128] Kidneys of six-day-old WAG-Rij rats were isolated,
homogenized, and trypsinized. Subconfluent dishes (diameter 5 cm)
of the BRK cell cultures were transfected with 1 or 5 .mu.g of
pIG.NEO, pIG.E1A.NEO, pIG.E1A.E1B, pIG.E1A.E1B.X, pAd5XhoIC, or
pIG.E1A.NEO together with PDC26 (Van der Elsen et al., 1983),
carrying the Ad5.E1B gene under control of the SV40 early promoter.
Three weeks post-transfection, when foci were visible, the dishes
were fixed, Giemsa stained, and the foci counted.
[0129] An overview of the generated adenovirus packaging constructs
and their ability to transform BRK is presented in FIG. 6. The
results indicate that the constructs pIG.E1A.E1B and pIG.E1A.E1B.X
are able to transform BRK cells in a dose-dependent manner. The
efficiency of transformation is similar for both constructs and is
comparable to what was found with the construct that was used to
make 911 cells, namely pAd5.XhoIC.
[0130] As expected, pIG.E1A.NEO was hardly able to immortalize BRK.
However, co-transfection of an E1B expression construct (PDC26) did
result in a significant increase in the number of transformants (18
versus 1), indicating that E1A encoded by pIG.E1A.NEO is
functional. We conclude, therefore, that the newly generated
packaging constructs are suited for the generation of new
adenovirus packaging lines.
Generation of Cell Lines with New Packaging Constructs, Cell Lines,
and Cell Culture
[0131] Human A549 bronchial carcinoma cells (Shapiro et al., 1978),
human embryonic retinoblasts ("HER"), Ad5-E1-transformed human
embryonic kidney ("HEK") cells (293; Graham et al., 1977), and
Ad5-transformed HER cells (911; Fallaux et al., 1996)) and PER
cells were grown in Dulbecco's Modified Eagle Medium ("DMEM")
supplemented with 10% Fetal Calf Serum ("FCS") and antibiotics in a
5% CO.sub.2 atmosphere at 37.degree. C. Cell culture media,
reagents, and sera were purchased from Gibco Laboratories (Grand
Island, N.Y.). Culture plastics were purchased from Greiner
(Nurtingen, Germany) and Corning (Corning, N.Y.).
Viruses and Virus Techniques
[0132] The construction of adenoviral vectors IG.Ad.MLP.nls.lacZ,
IG.Ad.MLP.luc, IG.Ad.MLP.TK, and IG.Ad.CMV.TK is described in
detail in European patent application EP 95202213. The recombinant
adenoviral vector IG.Ad.MLP.nls.lacZ contains the E. coli lacZ
gene, encoding .beta.-galactosidase, under control of the Ad2 major
late promoter ("MLP"). IG.Ad.MLP.luc contains the firefly
luciferase gene driven by the Ad2 MLP. Adenoviral vectors
IG.Ad.MLP.TK and IG.Ad.CMV.TR contain the Herpes Simplex Virus
thymidine kinase ("TK") gene under the control of the Ad2 MLP and
the Cytomegalovirus ("CMV") enhancer/promoter, respectively.
Transfections
[0133] All transfections were performed by calcium-phosphate
precipitation DNA (Graham and Van der Eb, 1973) with the GIBCO
Calcium Phosphate Transfection System (GIBCO BRL Life Technologies
Inc., Gaithersburg, Md., USA), according to the manufacturer's
protocol.
Western Blotting
[0134] Subconfluent cultures of exponentially growing 293, 911 and
Ad5-E1-transformed A549 and PER cells were washed with PBS and
scraped in Fos-RIPA buffer (10 mM Tris (pH 7.5), 150 mM NaCl, 1%
NP40, 01% sodium dodecyl sulphate ("SDS"), 1% NA-DOC, 0.5 mM phenyl
methyl sulphonyl fluoride ("PMSF"), 0.5 mM trypsin inhibitor, 50 mM
NaF and 1 mM sodium vanadate). After ten minutes at room
temperature, lysates were cleared by centrifugation. Protein
concentrations were measured with the Biorad protein assay kit, and
25 .mu.g total cellular protein was loaded on a 12.5% SDS-PAA gel.
After electrophoresis, proteins were transferred to nitrocellulose
(one hour at 300 mA). Prestained standards (Sigma, USA) were run in
parallel. Filters were blocked with 1% bovine serum albumin ("BSA")
in TBST (10 mM Tris, pH 8.15 mM NaCl, and 0.05% TWEEN.TM.-20) for
one hour. First antibodies were the mouse monoclonal
anti-Ad5-E1B-55-kDa antibody AIC6 (Zantema et al., unpublished),
the rat monoclonal anti-Ad5-E1B-221-kDa antibody CIGII (Zantema et
al., 1985). The second antibody was a horseradish
peroxidase-labeled goat anti-mouse antibody (Promega). Signals were
visualized by enhanced chemiluminescence (Amersham Corp, UK).
Southern Blot Analysis
[0135] High molecular weight DNA was isolated and 10 .mu.g was
digested to completion and fractionated on a 0.7% agarose gel.
Southern blot transfer to Hybond N+ (Amersham, UK) was performed
with a 0.4 M NaOH, 0.6 M NaCl transfer solution (Church and
Gilbert, 1984). Hybridization was performed with a 2463-nt
SspI-HindIII fragment from pAd5.SalB (Bernards et al., 1983). This
fragment consists of Ad5 bp. 342-2805. The fragment was
radiolabeled with .alpha.-.sup.32p-dCTP with the use of random
hexanucleotide primers and Klenow DNA polymerase. The Southern
blots were exposed to a Kodak XAR-5 film at -80.degree. C. and to a
Phospho-Imager screen that was analyzed by B&L Systems'
Molecular Dynamics software.
A549
[0136] Ad5-E1-transformed A549 human bronchial carcinoma cell lines
were generated by transfection with pIG.E1A.NEO and selection for
G418 resistance. Thirty-one G418-resistant clones were established.
Co-transfection of pIG.E1A.E1B with pIG.NEO yielded seven
G418-resistant cell lines.
PER
[0137] Ad5-E1-transformed HER cells were generated by transfection
of primary HER cells with plasmid pIG.E1A.E1B. Transformed cell
lines were established from well-separated foci. We were able to
establish seven clonal cell lines, which we called PER.C1, PER.C3,
PER.C4, PER.C5, PER.C6.TM., PER.C8, and PER.C9. One of the PER
clones, namely PER.C6.TM., has been deposited under the Budapest
Treaty under number ECACC.TM. 96022940 with the Centre for Applied
Microbiology and Research of Porton Down, UK, on Feb. 29, 1996. In
addition, PER.C6.TM. is commercially available from IngroGene,
B.V., Leiden, NL.
Expression of Ad5 E1A and E1B Genes in Transformed A549 and PER
Cells
[0138] Expression of the Ad5 E1A and the 55 kDa and 21 kDa E1B
proteins in the established A549 and PER cells was studied by means
of Western blotting with the use of monoclonal antibodies ("Mab").
Mab M73 recognizes the E1A products, whereas Mabs AIC6 and CIG11
are directed against the 55 kDa and 21 kDa E1B proteins,
respectively.
[0139] The antibodies did not recognize proteins in extracts from
the parental A549 or the primary HER cells (data not shown). None
of the A549 clones that were generated by co-transfection of
pIG.NEO- and pIG.E1A.E1B-expressed detectable levels of E1A or E1B
proteins (not shown). Some of the A549 clones that were generated
by transfection with pIG.E1A.NEO expressed the Ad5 E1A proteins
(see FIG. 7), but the levels were much lower than those detected in
protein lysates from 293 cells. The steady state E1A levels
detected in protein extracts from PER cells were much higher than
those detected in extracts from A549-derived cells. All PER cell
lines expressed similar levels of E1A proteins (FIG. 7). The
expression of the E1B proteins, particularly in the case of E1B 55
kDa, was more variable. Compared to 911 and 293, the majority of
the PER clones express high levels of E1B 55 kDa and 21 kDa. The
steady state level of E1B 21 kDa was the highest in PER.C3. None of
the PER clones lost expression of the Ad5 E1 genes upon serial
passage of the cells (not shown). We found that the level of E1
expression in PER cells remained stable for at least 100 population
doublings. We decided to characterize the PER clones in more
detail.
Southern Analysis of PER Clones
[0140] To study the arrangement of the Ad5-E1 encoding sequences in
the PER clones, we performed Southern analyses. Cellular DNA was
extracted from all PER clones and from 293 and 911 cells. The DNA
was digested with HindIII, which cuts once in the Ad5 E1 region.
Southern hybridization on HindIII-digested DNA, using a
radiolabeled Ad5-E1-specific probe, revealed the presence of
several integrated copies of pIG.E1A.E1B in the genome of the PER
clones. FIG. 8 shows the distribution pattern of E1 sequences in
the high molecular weight DNA of the different PER cell lines. The
copies are concentrated in a single band, which suggests that they
are integrated as tandem repeats. In the case of PER.C3, C5, C6,
and C9, we found additional hybridizing bands of low molecular
weight that indicate the presence of truncated copies of
pIG.E1A.E1B. The number of copies was determined with the use of a
Phospho-Imager. We estimated that PER.C1, C3, C4, C5, C6, C8, and
C9 contain 2, 88, 5, 4, 5, 5, and 3 copies of the Ad5 E1 coding
region, respectively, and that 911 and 293 cells contain 1 and 4
copies of the Ad5 E1 sequences, respectively.
Transfection Efficiency
[0141] Recombinant adenovectors are generated by co-transfection of
adaptor plasmids and the large ClaI fragment of Ad5 into 293 cells
(see European patent application EP 95202213). The recombinant
virus DNA is formed by homologous recombination between the
homologous viral sequences that are present in the plasmid and the
adenovirus DNA. The efficacy of this method, as well as that of
alternative strategies, is highly dependent on the transfectability
of the helper cells. Therefore, we compared the transfection
efficiencies of some of the PER clones with 911 cells, using the E.
coli .beta.-galactosidase-encoding lacZ gene as a reporter (see
FIG. 9).
Production of Recombinant Adenovirus
[0142] Yields of recombinant adenovirus obtained after inoculation
of 293, 911, PER.C3, PER.C5, and PER.C6.TM. with different
adenovirus vectors are presented in Table II. The results indicate
that the yields obtained on PER cells are at least as high as those
obtained on the existing cell lines. In addition, the yields of the
novel adenovirus vector IG.Ad.MLPI.TK are similar or higher than
the yields obtained for the other viral vectors on all cell lines
tested.
TABLE-US-00002 TABLE II Pas- sage Pro- num- IG.Ad. IG.Ad. IG.Ad.
ducer Cell ber CMV.lacZ CMV.TK MLPI.TK d1313 Mean 293 6.0 5.8 24 34
17.5 911 8 14 34 180 59.5 PER.C3 17 8 11 44 40 25.8 PER.C5 15 6 17
36 200 64.7 PER.C6 .TM. 36 10 22 58 320 102 Yields .times.
10.sup.-8 pfu/T175 flask.
[0143] Table II. Yields of different recombinant adenoviruses
obtained after inoculation of adenovirus E1 packaging cell lines
293, 911, PER.C3, PER.C5, and PER.C6.TM.. The yields are the mean
of two different experiments. IG.Ad.CMV.lacZ and IG.Ad.CMV.TK are
described in European patent application EP 95202213. The
construction of IG.Ad.MLPI.TK is described in this patent
application. Yields of virus per T80 flask were determined by
plaque assay on 911 cells, as described [Fallaux, 1996 #1493].
Generation of New Adenovirus Vectors
[0144] The used recombinant adenovirus vectors (see European patent
application EP 95202213) are deleted for E1 sequences from nt. 459
to nt. 3328.
[0145] As construct pE1A.E1B contains Ad5 sequences nt. 459 to nt.
3510, there is a sequence overlap of 183 nt. between E1B sequences
in the packaging construct pIG.E1A.E1B and recombinant
adenoviruses, such as, for example, IG.Ad.MLP.TK. The overlapping
sequences were deleted from the new adenovirus vectors. In
addition, non-coding sequences derived from lacZ, which are present
in the original constructs, were deleted as well. This was achieved
(see FIG. 10) by PCR amplification of the SV40 poly(A) sequences
from pMLP.TK using primers SV40-1 (SEQ ID NO:8) (introduces a BamHI
site) and SV40-2 (SEQ ID NO:9) (introduces a BglII site). In
addition, Ad5 sequences present in this construct were amplified
from nt. 2496 (Ad5-1 (SEQ ID NO:10), introduces a BglII site) to
nt. 2779 (Ad5-2 (SEQ ID NO: 11)). Both PCR fragments were digested
with BglII and were ligated. The ligation product was PCR amplified
using primers SV40-1 (SEQ ID NO:8) and Ad5-2 (SEQ ID NO:11). The
PCR product obtained was cut with BamHI and AflII and was ligated
into pMLP.TK predigested with the same enzymes. The resulting
construct, named pMLPI.TK, contains a deletion in adenovirus E1
sequences from nt. 459 to nt. 3510.
Packaging System
[0146] The combination of the new packaging construct pIG.E1A.E1B
and the recombinant adenovirus pMLPI.TK, which do not have any
sequence overlap, are presented in FIGS. 11A and 11B. In these
figures, the original situation is also presented with the sequence
overlap indicated.
[0147] The absence of overlapping sequences between pIG.E1A.E1B and
pMLPI.TK (FIG. 11A) excludes the possibility of homologous
recombination between packaging construct and recombinant virus,
and is therefore a significant improvement for production of
recombinant adenovirus as compared to the original situation.
[0148] In FIG. 11B, the situation is depicted for pIG.E1A.NEO and
IG.Ad.MLPI.TK. pIG.E1A.NEO, when transfected into established
cells, is expected to be sufficient to support propagation of
E1-deleted recombinant adenovirus. This combination does not have
any sequence overlap, preventing generation of RCA by homologous
recombination. In addition, this convenient packaging system allows
the propagation of recombinant adenoviruses that are deleted just
for E1A sequences and not for E1B sequences. Recombinant
adenoviruses expressing E1B in the absence of E1A are attractive,
as the E1B protein, in particular E1B 19 kDa, is able to prevent
infected human cells from lysis by Tumor Necrosis Factor ("TNF")
(Gooding et al., 1991).
Generation of Recombinant Adenovirus Derived from pMLPI.TK
[0149] Recombinant adenovirus was generated by co-transfection of
293 cells with SalI linearized pMLPI.TK DNA and ClaI linearized Ad5
wt DNA. The procedure is schematically represented in FIG. 12.
Outline of the Strategy to Generate Packaging Systems for Minimal
Adenovirus Vector
[0150] Name convention of the plasmids used: [0151] p plasmid
[0152] I ITR (Adenovirus Inverted Terminal Repeat) [0153] C CMV
Enhancer/Promoter Combination [0154] L Firefly Luciferase Coding
Sequence hac, haw Potential hairpin that can be formed after
digestion with restriction endonuclease Asp718 in its correct and
in the reverse orientation, respectively (FIG. 15 (SEQ ID
NO:22)).
[0155] For example, pICLhaw is a plasmid that contains the
adenovirus ITR followed by the CMV-driven luciferase gene and the
Asp718 hairpin in the reverse (non-functional) orientation.
[0156] Experiment Series 1
[0157] The following demonstrates the competence of a synthetic DNA
sequence that is capable of forming a hairpin-structure to serve as
a primer for reverse strand synthesis for the generation of
double-stranded DNA molecules in cells that contain and express
adenovirus genes.
[0158] Plasmids pICLhac, pICLhaw, pICLI and pICL (SEQ ID NO:21)
were generated using standard techniques. The schematic
representation of these plasmids is shown in FIGS. 16-19.
[0159] Plasmid pICL (SEQ ID NO:21) is derived from the following
plasmids: [0160] nt. 11-457 pMLP10 (Levrero et al., 1991); [0161]
nt. 458-1218 pCMV.beta. (Clontech, EMBL Bank No. U02451); [0162]
nt. 1219-3016 pMLP.luc (IntroGene, Leiden, NL, unpublished); and
[0163] nt. 3017-5620 pBLCAT5 (Stein and Whelan, 1989).
[0164] The plasmid has been constructed as follows:
[0165] The tet gene of plasmid pMLP10 has been inactivated by
deletion of the BamHI-SalI fragment to generate pMLP10.DELTA.SB.
Using primer set PCR/MLPI (SEQ ID NO:14) and PCR/MLP3 (SEQ ID
NO:16), a 210 bp fragment containing the Ad5-ITR, flanked by a
synthetic SalI restriction site, was amplified using pMLP10 DNA as
the template. The PCR product was digested with the enzymes EcoRI
and SgrAI to generate a 196 bp fragment. Plasmid pMLP10.DELTA.SB
was digested with EcoRI and SgrAI to remove the ITR. This fragment
was replaced by the EcoRI-SgrAI-treated PCR fragment to generate
pMLP/SAL. Plasmid pCMV-Luc was digested with PvuII to completion
and recirculated to remove the SV40-derived poly-adenylation signal
and Ad5 sequences with exception of the Ad5 left-terminus. In the
resulting plasmid, pCMV-luc.DELTA.Ad, the Ad5 ITR was replaced by
the Sal-site-flanked ITR from plasmid pMLP/SAL by exchanging the
XmnI-SacII fragments. The resulting plasmid, pCMV-luc.DELTA.Ad/SAL,
the Ad5 left terminus, and the CMV-driven luciferase gene were
isolated as an SalI-SmaI fragment and inserted in the SalI and HpaI
digested plasmid pBLCATS to form plasmid pICL (SEQ ID NO:21).
Plasmid pICL is represented in FIG. 19; its sequence is presented
in FIGS. 20A-20F (SEQ ID NO:21).
[0166] The plasmid pICL (SEQ ID NO:21) contains the following
features: [0167] nt. 1-457 Ad5 left terminus (Sequence 1-457 of
human adenovirus type 5); [0168] nt. 458-969 Human cytomegalovirus
enhancer and immediate early promoter (see Boshart et al., A Very
Strong Enhancer is Located Upstream of an Immediate Early Gene of
Human Cytomegalovirus", Cell 41, pp. 521-530 (1985), hereby
incorporated herein by reference) (from plasmid pCMV.beta.,
Clontech, Palo Alto, USA); [0169] nt. 970-1204 SV40 19S exon and
truncated 16/19S intron (from plasmid pCMV.beta.); [0170] nt.
1218-2987 Firefly luciferase gene (from pMLP.luc); [0171] nt.
3018-3131 SV40 tandem poly-adenylation signals from late
transcript, derived from plasmid pBLCAT5); [0172] nt. 3132-5620
pUC12 backbone (derived from plasmid pBLCAT5); and [0173] nt.
4337-5191 .beta.-lactamase gene (Amp-resistance gene, reverse
orientation). Plasmid pICLhac and pICLhaw
[0174] Plasmids pICLhac and pICLhaw were derived from plasmid pICL
(SEQ ID NO:21) by digestion of the latter plasmid with the
restriction enzyme Asp718. The linearized plasmid was treated with
Calf-Intestine Alkaline Phosphatase to remove the 51 phosphate
groups. The partially complementary synthetic single-stranded
oligonucleotide Hp/asp1 (SEQ ID NO:17) and Hp/asp2 (SEQ ID NO:18)
were annealed and phosphorylated on their 5' ends using
T4-polynucleotide kinase.
[0175] The phosphorylated double-stranded oligomers were mixed with
the dephosphorylated pICL fragment and ligated. Clones containing a
single copy of the synthetic oligonucleotide inserted into the
plasmid were isolated and characterized using restriction enzyme
digests. Insertion of the oligonucleotide into the Asp718 site will
at one junction recreate an Asp718 recognition site, whereas at the
other junction, the recognition site will be disrupted. The
orientation and the integrity of the inserted oligonucleotide were
verified in selected clones by sequence analyses. A clone
containing the oligonucleotide in the correct orientation (the
Asp718 site close to the 3205 EcoRI site) was denoted pICLhac. A
clone with the oligonucleotide in the reverse orientation (the
Asp718 site close to the SV40-derived poly signal) was designated
pICLhaw. Plasmids pICLhac and pICLhaw are represented in FIGS. 16
and 17.
[0176] Plasmid pICLI was created from plasmid pICL (SEQ ID NO:21)
by insertion of the SalI-SgrAI fragment from pICL containing the
Ad5-ITR into the Asp718 site of pICL. The 194 bp SalI-SgrAI
fragment was isolated from pICL (SEQ ID NO:21), and the cohesive
ends were converted to blunt ends using E. coli DNA polymerase I
(Klenow fragment) and dNTPs. The Asp718 cohesive ends were
converted to blunt ends by treatment with mungbean nuclease. Clones
were generated by ligation that contain the ITR in the Asp718 site
of plasmid pICL (SEQ ID NO:21). A clone that contained the ITR
fragment in the correct orientation was designated pICLI (see FIG.
18). Generation of adenovirus Ad-CMV-hcTK: recombinant adenovirus
was constructed according to the method described in European
patent application EP 95202213. Two components are required to
generate a recombinant adenovirus. First, an adaptor-plasmid
containing the left terminus of the adenovirus genome containing
the ITR and the packaging signal, an expression cassette with the
gene of interest, and a portion of the adenovirus genome which can
be used for homologous recombination. In addition, adenovirus DNA
is needed for recombination with the aforementioned adaptor
plasmid. In the case of Ad-CMV-hcTK, the plasmid PCMV.TK was used
as a basis. This plasmid contains nt. 1-455 of the adenovirus type
5 genome, nt. 456-1204 derived from pCMVP (Clontech, the PstI-StuI
fragment that contains the CMV enhancer promoter and the 16S/19S
intron from Simian Virus 40), the HSV TK gene (described in
European patent application EP 95202213), the SV40-derived
polyadenylation signal (nt 2533-2668 of the SV40 sequence),
followed by the BglII-ScaI fragment of Ad5 (nt. 3328-6092 of the
Ad5 sequence). These fragments are present in a pMLP10-derived
(Levrero et al., 1991) backbone. To generate plasmid pAD-CMVhc-TK,
plasmid pCMV.TK was digested with ClaI (the unique ClaI-site is
located just upstream of the TK open reading frame) and
dephosphorylated with Calf-Intestine Alkaline Phosphate. To
generate a hairpin-structure, the synthetic oligonucleotides
HP/cla1 (SEQ ID NO:19) and HP/cla2 (SEQ ID NO:20) were annealed and
phosphorylated on their 5-OH groups with T4-polynucleotide kinase
and ATP. The double-stranded oligonucleotide was ligated with the
linearized vector fragment and used to transform E. coli strain
"Sure". Insertion of the oligonucleotide into the ClaI site will
disrupt the ClaI recognition sites. The oligonucleotide contains a
new ClaI site near one of its termini. In selected clones, the
orientation and the integrity of the inserted oligonucleotide was
verified by sequence analyses. A clone containing the
oligonucleotide in the correct orientation (the ClaI site at the
ITR side) was denoted pAd-CMV-hcTK. This plasmid was co-transfected
with ClaI digested wild-type Adenovirus type 5 DNA into 911 cells.
A recombinant adenovirus in which the CMV-hcTK expression cassette
replaces the E1 sequences was isolated and propagated using
standard procedures.
[0177] To study whether the hairpin can be used as a primer for
reverse strand synthesis on the displaced strand after replication
had started at the ITR, the plasmid pICLhac is introduced into 911
cells (human embryonic retinoblasts transformed with the adenovirus
E1 region). The plasmid pICLhaw serves as a control, which contains
the oligonucleotide pair HP/asp1 (SEQ ID NO:17) and HP/asp2 (SEQ ID
NO:18) in the reverse orientation but is further completely
identical to plasmid pICLhac. Also included in these studies are
plasmids pICLI and pICL (SEQ ID NO:21). In the plasmid pICLI, the
hairpin is replaced by an adenovirus ITR. Plasmid pICL (SEQ ID
NO:21) contains neither a hairpin nor an ITR sequence. These
plasmids serve as controls to determine the efficiency of
replication by virtue of the terminal-hairpin structure. To provide
the viral products other than the E1 proteins (these are produced
by the 911 cells) required for DNA replication, the cultures are
infected with the virus IG.Ad.MLPI.TK after transfection. Several
parameters are being studied to demonstrate proper replication of
the transfected DNA molecules. First, DNA extracted from the cell
cultures transfected with aforementioned plasmids and infected with
IG.Ad.MLPI.TK virus is being analyzed by Southern blotting for the
presence of the expected replication intermediates, as well as for
the presence of the duplicated genomes. Furthermore, virus is
isolated from the transfected and IG.Ad.MLPI.TK infected cell
populations that is capable of transferring and expressing a
luciferase marker gene into luciferase negative cells.
[0178] Plasmid DNA of plasmids pICLhac, pICLhaw, pICLI, and pICL
(SEQ ID NO:21) have been digested with restriction endonuclease
SalI and treated with mungbean nuclease to remove the 4 nucleotide
single-stranded extension of the resulting DNA fragment. In this
manner, a natural adenovirus 5' ITR terminus on the DNA fragment is
created. Subsequently, both the pICLhac and pICLhaw plasmids were
digested with restriction endonuclease Asp718 to generate the
terminus capable of forming a hairpin structure. The digested
plasmids are introduced into 911 cells, using the standard calcium
phosphate co-precipitation technique, four dishes for each plasmid.
During the transfection, for each plasmid two of the cultures are
infected with the IG.Ad.MLPI.TK virus using five infectious
IG.Ad.MLPI.TK particles per cell. At twenty-hours post-transfection
and forty hours post-transfection, one Ad.tk-virus-infected and one
uninfected culture are used to isolate small molecular-weight DNA
using the procedure devised by Hirt. Aliquots of isolated DNA are
used for Southern analysis. After digestion of the samples with
restriction endonuclease EcoRI using the luciferase gene as a
probe, a hybridizing fragment of approximately 2.6 kb is detected
only in the samples from the adenovirus infected cells transfected
with plasmid pICLhac. The size of this fragment is consistent with
the anticipated duplication of the luciferase marker gene. This
supports the conclusion that the inserted hairpin is capable of
serving as a primer for reverse strand synthesis. The hybridizing
fragment is absent if the IG.Ad.MLPI.TK virus is omitted or if the
hairpin oligonucleotide has been inserted in the reverse
orientation.
[0179] The restriction endonuclease DpnI recognizes the
tetranucleotide sequence 5'-GATC-3' but cleaves only methylated DNA
(that is, only plasmid DNA propagated in and derived from E. coli,
not DNA that has been replicated in mammalian cells). The
restriction endonuclease MboI recognizes the same sequences, but
cleaves only unmethylated DNA (viz. DNA propagated in mammalian
cells). DNA samples isolated from the transfected cells are
incubated with MboI and DpnI and analyzed with Southern blots.
These results demonstrate that only in the cells transfected with
the PICLhac and the pICLI plasmids are large DpnI-resistant
fragments present that are absent in the MboI treated samples.
These data demonstrate that only after transfection of plasmids
pICLI and pICLhac does replication and duplication of the fragments
occur.
[0180] These data demonstrate that in adenovirus-infected cells,
linear DNA fragments that have on one terminus an
adenovirus-derived ITR and at the other terminus a nucleotide
sequence that can anneal to sequences on the same strand when
present in single-stranded form, thereby generate a hairpin
structure and will be converted to structures that have inverted
terminal repeat sequences on both ends. The resulting DNA molecules
will replicate by the same mechanism as the wild-type adenovirus
genomes.
[0181] Experiment Series 2
[0182] The following demonstrates that the DNA molecules that
contain a luciferase marker gene, a single copy of the ITR, the
encapsidation signal, and a synthetic DNA sequence that is capable
of forming a hairpin structure are sufficient to generate DNA
molecules that can be encapsidated into virions.
[0183] To demonstrate that the above DNA molecules containing two
copies of the CMV-luc marker gene can be encapsidated into virions,
virus is harvested from the remaining two cultures via three cycles
of freeze-thaw crushing and is used to infect murine fibroblasts.
Forty-eight hours after infection, the infected cells are assayed
for luciferase activity. To exclude the possibility that the
luciferase activity has been induced by transfer of free DNA,
rather than via virus particles, virus stocks are treated with
DNaseI to remove DNA contaminants. Furthermore, as an additional
control, aliquots of the virus stocks are incubated for 60 minutes
at 56.degree. C. The heat treatment will not affect the
contaminating DNA but will inactivate the viruses. Significant
luciferase activity is only found in the cells after infection with
the virus stocks derived from IG.Ad.MLPI.TK-infected cells
transfected with the pICLhc and pICLI plasmids. In neither the
non-infected cells nor the infected cells transfected with the
pICLhw and pICL (SEQ ID NO:21) can significant luciferase activity
be demonstrated. Heat inactivation, but not DNaseI treatment,
completely eliminates luciferase expression, demonstrating that
adenovirus particles, and not free (contaminating) DNA fragments,
are responsible for transfer of the luciferase reporter gene.
[0184] These results demonstrate that these small viral genomes can
be encapsidated into adenovirus particles and suggest that the ITR
and the encapsidation signal are sufficient for encapsidation of
linear DNA fragments into adenovirus particles. These adenovirus
particles can be used for efficient gene transfer. When introduced
into cells that contain and express at least part of the adenovirus
genes (viz. E1, E2, E4, and L, and VA), recombinant DNA molecules
that consist of at least one ITR, at least part of the
encapsidation signal, and a synthetic DNA sequence that is capable
of forming a hairpin structure have the intrinsic capacity to
autonomously generate recombinant genomes that can be encapsidated
into virions. Such genomes and vector system can be used for gene
transfer.
[0185] Experiment Series 3
[0186] The following demonstrates that DNA molecules that contain
nucleotides 3510-35953 (viz. 9.7-100 map units) of the adenovirus
type 5 genome (thus lacking the E1 protein-coding regions, the
right-hand ITR, and the encapsidation sequences) and a terminal DNA
sequence that is complementary to a portion of the same strand of
the DNA molecule when present in single-stranded form other than
the ITR, and as a result is capable of forming a hairpin structure,
can replicate in 911 cells.
[0187] In order to develop a replicating DNA molecule that can
provide the adenovirus products required to allow the above
mentioned ICLhac vector genome and alike minimal adenovectors to be
encapsidated into adenovirus particles by helper cells, the
Ad-CMV-hcTK adenoviral vector has been developed. Between the CMV
enhancer/promoter region and the thymidine kinase gene, the
annealed oligonucleotide pair HP/cla1 (SEQ ID NO:19) and 2 (SEQ ID
NO:20) is inserted. The vector Ad-CMV-hcTK can be propagated and
produced in 911 cell using standard procedures. This vector is
grown and propagated exclusively as a source of DNA used for
transfection. DNA of the adenovirus Ad-CMV-hcTK is isolated from
virus particles that had been purified using CsC1 density-gradient
centrifugation by standard techniques. The virus DNA has been
digested with restriction endonuclease ClaI. The digested DNA is
size-fractionated on a 0.7% agarose gel, and the large fragment is
isolated and used for further experiments. Cultures of 911 cells
are transfected large ClaI-fragment of the Ad-CMV-hcTK DNA using
the standard calcium phosphate co-precipitation technique. Much
like in the previous experiments with plasmid plCLhac, the
AD-CMV-hc will replicate starting at the right-hand ITR. Once the
1-strand is displaced, a hairpin can be formed at the left-hand
terminus of the fragment. This facilitates the DNA polymerase to
elongate the chain towards the right-hand-side. The process will
proceed until the displaced strand is completely converted to its
double-stranded form. Finally, the right-hand ITR will be
recreated, and in this location the normal adenovirus
replication-initiation and elongation will occur. Note that the
polymerase will read through the hairpin, thereby duplicating the
molecule. The input DNA molecule of 33250 bp, which had on one side
an adenovirus ITR sequence and at the other side a DNA sequence
that had the capacity to form a hairpin structure, has now been
duplicated in a way that both ends contain an ITR sequence. The
resulting DNA molecule will consist of a palindromic structure of
approximately 66500 bp.
[0188] This structure can be detected in low-molecular weight DNA
extracted from the transfected cells using Southern analysis. The
palindromic nature of the DNA fragment can be demonstrated by
digestion of the low-molecular weight DNA with suitable restriction
endonucleases and Southern blotting with the HSV-TK gene as the
probe. This molecule can replicate itself in the transfected cells
by virtue of the adenovirus gene products that are present in the
cells. In part, the adenovirus genes are expressed from templates
that are integrated in the genome of the target cells (viz. the E1
gene products), the other genes reside in the replicating DNA
fragment itself. Note however, that this linear DNA fragment cannot
be encapsidated into virions. Not only does it lack all the DNA
sequences required for encapsidation, but also is its size is also
much too large to be encapsidated.
[0189] Experiment Series 4
[0190] The following demonstrates that DNA molecules that contain
nucleotides 3503-35953 (viz. 9.7-100 map units) of the adenovirus
type 5 genome (thus lacking the E1 protein-coding regions, the
right-hand ITR, and the encapsidation sequences) and a terminal DNA
sequence that is complementary to a portion the same strand of the
DNA molecule other than the ITR, and as a result is capable of
forming a hairpin structure, can replicate in 911 cells and can
provide the helper functions required to encapsidate the pICLI- and
pICLhac-derived DNA fragments.
[0191] The following series of experiments aims to demonstrate that
the DNA molecule described in Experiment Series 3 could be used to
encapsidate the minimal adenovectors described in Experiment Series
1 and 2.
[0192] In the experiments, the large fragment isolated after
endonuclease ClaI-digestion of Ad-CMV-hcTK DNA is introduced into
911 cells (in conformity with the experiments described in part
1.3) together with endonuclease SalI, mungbean nuclease,
endonuclease Asp718-treated plasmid pICLhac, or, as a control,
similarly treated plasmid pICLhaw. After 48 hours, virus is
isolated by freeze-thaw crushing of the transfected cell
population. The virus-preparation is treated with DNaseI to remove
contaminating free DNA. The virus is used subsequently to infect
Rat2 fibroblasts. Forty-eight hours post infection, the cells are
assayed for luciferase activity. Significant luciferase activity
can be demonstrated only in the cells infected with virus isolated
from the cells transfected with the pICLhac plasmid and not with
the pICLhaw plasmid. Heat inactivation of the virus prior to
infection completely abolishes the luciferase activity, indicating
that the luciferase gene is transferred by a viral particle.
Infection of 911 cell with the virus stock did not result in any
cytopathological effects, demonstrating that the pICLhac is
produced without any infectious helper virus that can be propagated
on 911 cells. These results demonstrate that the proposed method
can be used to produce stocks of minimal adenoviral vectors that
are completely devoid of infectious helper viruses and are able to
replicate autonomously on adenovirus-transformed human cells or on
non-adenovirus transformed human cells.
[0193] Besides the system described in this application, another
approach for the generation of minimal adenovirus vectors has been
disclosed in International Patent Publication WO 94/12649. The
method described in WO 94/12649 exploits the function of the
protein IX for the packaging of minimal adenovirus vectors (Pseudo
Adenoviral Vectors ("PAV") in the terminology of WO 94/12649). PAVs
are produced by cloning an expression plasmid with the gene of
interest between the left-hand (including the sequences required
for encapsidation) and the right-hand adenoviral ITRs. The PAV is
propagated in the presence of a helper virus. Encapsidation of the
PAV is preferred compared with the helper virus because the helper
virus is partially defective for packaging (either by virtue of
mutations in the packaging signal or by virtue of its size, virus
genomes greater than 37.5 kb package inefficiently). In addition,
the authors propose that in the absence of the protein IX gene, the
PAV will be preferentially packaged. However, neither of these
mechanisms appear to be sufficiently restrictive to allow packaging
of only PAVs/minimal vectors. The mutations proposed in the
packaging signal diminish packaging but do not provide an absolute
block, as the same packaging-activity is required to propagate the
helper virus. Also, neither an increase in the size of the helper
virus nor the mutation of the protein IX gene will ensure that PAV
is packaged exclusively. Thus, the method described in WO 94/12649
is unlikely to be useful for the production of helper-free stocks
of minimal adenovirus vectors/PAVs.
[0194] Although the application has been described with reference
to certain preferred embodiments and illustrative examples, the
scope of the invention is to be determined by reference to the
appended claims.
REFERENCES
[0195] Berk A. J. (1986), Ann. Rev. Genet. 20, 45-79. [0196]
Bernards R., P. I. Schrier, J. L. Bos and A. J. van der Eb (1983),
role of adenovirus types 5 and 12 early region 1b tumor antigens in
oncogenic transformation. Virology 127, 45-53. [0197] Bett A. J, L.
Prevec and F. L. Graham (1993), Packaging Capacity and Stability of
Human Adenovirus Type-5 Vectors. J. Virol. 67, 5911-5921. [0198]
Blaese M., T. Blankenstein, M. Brenner, O. Cohen-Hageenauer, B.
Gansbacher, S. Russell, B. Sorrentino and T. Velu (1995), vectors
in cancer therapy: how will they deliver? Cancer Gene Ther. 2,
291-297. [0199] Boshart M., F. Weber, G. Jahn, K. Dorsch-Haler, B.
Fleckenstein and W. Scaffner (1985), a very strong enhancer is
located upstream of an immediate early gene of human
Cytomegalovirus. Cell 41, 521-530. [0200] Bout A., J. L. Imler, H.
Schulz, M. Perricaudet, C. Zurcher, P. Herbrink, D. Valerio and A.
Pavirani (1994a), in vivo adenovirus-mediated transfer of human
CFTR cDNA to Rhesus monkey airway epithelium: efficacy, toxicity
and safety. Gene Therapy 1, 385-394. [0201] Bout A., M.
Perricaudet, G. Baskin, J. L. Imler, B. J. Scholte, A. Pavirani and
D. Valerio (1994b), lung gene therapy: in vivo adenovirus-mediated
gene transfer to rhesus monkey airway epithelium. Human Gene
Therapy 5, 3-10. [0202] Brody S. L. and R. G. Crystal (1994),
adenovirus-mediated in vivo gene transfer. Ann. N.Y. Acad. Sci.
716, 90-101. [0203] Brough D. E., V. Cleghon and D. F. Klessig
(1992), construction, characterization, and utilization of cell
lines which inducibly express the adenovirus DNA-binding protein.
Virology 190(2), 624-34. [0204] Brough D. E., S. A. Rice, S. Sell
and D. F. Klessig (1985), restricted changes in the adenovirus
DNA-binding protein that lead to extended host range or
temperature-sensitive phenotypes. J. Virol. 55, 206-212. [0205]
Daniell E. (1976), genome structure of incomplete particles of
adenovirus. J. Virol. 19, 685-708. [0206] van der Elsen P. J., A.
Houweling and A. J. van der Eb (1983), expression of region E1B of
human adenoviruses in the absence of region E1A is not sufficient
for complete transformation. Virology 128, 377-390. [0207]
Engelhardt J. F., L. Litzky and J. M. Wilson (1994a), prolonged
transgene expression in cotton rat lung with recombinant
adenoviruses defective in E2A. Human Gene Therapy 5, 1217-1229.
[0208] Engelhardt J. F., R. H. Simon, Y. Yang, M. Zepeda, S.
Weber-Pendleton, B. Doranz, M. Grossman and J. M. Wilson (1993),
adenovirus-mediated transfer of the CFFR gene to lung or nonhuman
primates: biological efficacy study. Human Gene Therapy 4, 759-769.
[0209] Engelhardt J. F., X. Ye, B. Doranz and J. M. Wilson (1994b),
ablation of E2A in recombinant adenoviruses improves transgene
persistence and decreases inflammatory response in mouse liver.
Proc. Nat'l Acad. Sci. USA 91, 6196-200. [0210] Fang B., H. Wang,
G. Gordon, D. A. Bellinger, M. S. Read, K. M. Brinkhous, S. L. C.
Woo and R. C. Eisensmith (1996), lack of persistence of
E1-recombinant adenoviral vectors containing a
temperature-sensitive E2A mutation in immunocompetent mice and
hemophilia dogs. Gene Therapy 3, 217-222. [0211] Fallaux F. J., O.
Kranenburg, S. J. Cramer, A. Houweling, H. von Ormondt, R. C.
Hoeben and A. J. van der Eb (1996), characterization of 911: a new
helper cell line for the titration and propagation of early region
1-deleted adenoviral vectors. Human Gene Therapy 7, 215-222. [0212]
Gooding L. R., L. Aquino, P. J. Duerksen-Hughes, D. Day, T. M.
Horton, S. Yei and W. S. M. Wold (1991), the E1B
19,000-molecular-weight protein of group C adenoviruses prevents
tumor necrosis factor cytolysis of human cells but not of mouse
cells. J. Virol. 65, 3083-3094. [0213] Grable M. and P. Hearing
(1990), adenovirus type 5 packaging domain is composed of a
repeated element that is functionally redundant. J. Virol. 64,
2047-2056. [0214] Grable M. and P. Hearing (1992), cis and trans
Requirements for the Selective Packaging of Adenovirus Type-5 DNA.
J. Virol. 66, 723-731. [0215] Graham F. L. and A. J. van der Eb
(1973), a new technique for the assay of infectivity of human
adenovirus 5 DNA. Virology 52, 456-467. [0216] Graham F. L., J.
Smiley, W. C. Russell and R. Naira (1977), characteristics of a
human cell line transformed by DNA from adenovirus type 5. J. Gen.
Virol. 36, 59-72. [0217] Haddada H., T. Ragot, L. Cordier, M. T.
Duffour and M. Perricaudet (1993), adenoviral interleukin-2 gene
transfer into P815 tumor cells abrogates tumorigenicity and induces
antitumoral immunity in mice. Human Gene Therapy 4, 703-11. [0218]
Hay R. T., N. D. Stow and I. M. McDougall (1984), replication of
adenovirus minichromosomes. J. Mol. Biol. 174, 493-510. [0219]
Hearing P., R. J. Samulski, W. L. Wishart and T. Shenk (1987),
identification of a repeated sequence element required for
efficient encapsidation of the adenovirus type 5 chromosome. J.
Virol. 61, 2555-2558. [0220] Horwitz M. S. (1990), Adenoviridae and
Their Replication, pp. 1679-1740, in B. N. Fields and D. M. Knipe
(Eds), Virology, Raven Press, Ltd, New York. [0221] Hu C. H., F. Y.
Xu, K. Wang, A. N. Pearson and G. D. Pearson (1992), Symmetrical
Adenovirus Minichromosomes Have Hairpin Replication Intermediates.
Gene 110, 145-150. [0222] Imler J. L., C. Chartier, D. Dreyer, A.
Dieterle, M. Sainte-Marie, T. Faure, A. Pavirani and M. Mehtali
(1996), novel complementation cell lines derived from human lung
carcinoma A549 cells support the growth of E1-deleted adenovirus
vectors. Gene Ther. 3, 75-84. [0223] Jochemsen A. G., L. T. C.
Peltenburg, M. F. W. T. Pas, C. M. de Wit, J. L. Bos and A. J. van
der Eb (1987). EMBO J. 6, 3399-3405. [0224] Klessig D. F. and T.
Grodzicker (1979), mutations that allow human Ad2 and Ad5 to
express late genes in monkey cells maps in the viral gene encoding
the 72K DNA-binding protein. Cell 17, 957-566. [0225] Klessig D.
F., T. Grodzicker and V. Cleghon (1984), construction of human cell
lines which contain and express the adenovirus DNA binding protein
gene by co-transformation with the HSV-1 tk gene. Virus Res. 1,
169-188. [0226] Kruijer W., J. C. Nicolas, F. M. von Schaik and J.
S. Sussenbach (1983), structure and function of DNA binding
proteins from revertants of adenovirus type 5 mutants with a
temperature-sensitive DNA replication. Virology 124, 425-433.
[0227] Lechner R. L. and T. J. Kelly Jr. (1977), the structure of
replicating adenovirus 2 DNA molecules. J. Mol. Biol. 174, 493-510.
[0228] de Leij L., P. E. Postmus, C. H. C. M. Buys, J. D. Elema, F.
Ramaekers, S. Poppema, M. Brouwer, A. Y. van der Veen, G. Mesander
and T. H. The (1985), characterization of three new variant type
cell lines derived from small cell carcinoma of the lung. Cancer
Res. 45, 6024-6033. [0229] Levrero M., V. Barban, S. Manteca, A.
Ballay, C. Balsamo, M. L. Avantaggiati, G. Natoli, H. Skellekens,
P. Tiollais and M. Perricaudet (1991), defective and nondefective
adenovirus vectors for expressing foreign genes in vitro and in
vivo. Gene 101, 195-202. [0230] Lochmuller H., A. Jani, J. Huard,
S. Prescott, M. Simoneau, B. Massie, G. Karpati and G. Acasdi
(1994), emergence of early region 1-containing
replication-competent adenovirus in stocks of replication-defective
adenovirus recombinants (.DELTA.E1-.DELTA.E3) during multiple
passages in 293 cells. Hum. Gene Ther. 5, 1485-1492. [0231] Matsui
T., M. Murayama and T. Mita (1986), adenovirus 2 peptide IX is
expressed only on replicated DNA molecules. Mol. Cell. Biol. 6,
4149-4154. [0232] Michelson A. M., A. F. Markham and S. H. Orkin
(1983), isolation and DNA sequence of a full-length cDNA clone for
human X-chromosome-encoded phosphoglycerate kinase. Proc. Nat'l.
Acad. Sci. USA 80, 472-476. [0233] Morin J. E., M. D. Lubeck, J. E.
Barton, A. J. Conley, A. R. Davis and P. P. Hung (1987),
recombinant adenovirus induces antibody response to hepatitis B
virus surface antigens. Proc. Nat'l. Acad. Sci. USA, 84, 4626-4630.
[0234] Nicolas J. C., F. Suarez, A. J. Levine and M. Girard (1981),
temperature-independent revertants of adenovirus H5ts125 and
H5ts107 mutants in the DNA binding protein: isolation of a new
class of host range temperature conditional revertants. Virology
108, 521-524. [0235] Ostrove J. M. (1994), safety testing programs
for gene therapy viral vectors. Cancer Gene Therapy 1, 125-131.
[0236] Pacini D. L., E. J. Dubovi and W. A. Clyde (1984), J.
Infect. Dis. 150, 92-97. [0237] Postmus P. E., L. de Ley, A. Y. van
der Veen, G. Mesander, C. H. C. M. Buys and J. D. Elema, (1988),
two small cell lung cancer cell lines established from rigid
bronchoscope biopsies. Eur. J. Clin. Oncol. 24, 753-763. [0238]
Rice S. A. and D. F. Klessig (1985), isolation and analysis of
adenovirus type 5 mutants containing deletions in the gene encoding
the DNA-binding protein. J. Virol. 56, 767-778. [0239] Roberts B.
E., J. S. Miller, D. Kimelman, C. L. Cepko, I. R. Lemischka and R.
C. Mulligan (1985), J. Virol. 56, 404-413. [0240] Shapiro D. L., L.
L. Nardone, S. A. Rooney, E. K. Motoyama and J. L. Munoz (1978),
phospholipid biosynthesis and secretion by a cell line (A549) which
resembles type II alveolar epithelial cells. Biochim. Biophys.
Acta. 530, 197-207. [0241] Simon R. H., J. F. Engelhardt, Y. Yang,
M. Zepeda, S. Weber-Pendleton, M. Grossman and J. M. Wilson (1993),
adenovirus-mediated transfer of the CFTR gene to lung of nonhuman
primates: toxicity study. Human Gene Therapy 4, 771-780. [0242]
Singer-Sam J., D. H. Keith, K. Tani, R. L. Simmer, L. Shively, S.
Lindsay, A. Yoshida and A. D. Riggs (1984), sequence of the
promoter region of the gene for X-linked 3-phosphoglycerate kinase.
Gene 32, 409-417. [0243] Stein R. W. and J. Whelan (1989), insulin
gene enhancer activity is inhibited by adenovirus 5 E1A gene
products. Mol. Cell. Biol. 9, 4531-4. [0244] Stratford-Perricaudet
L. D. and M. Perricaudet (1991), Gene Transfer into Animals: the
Promise of Adenovirus, pp. 51-61, in O. Cohen-Adenauer and M.
Boiron (Eds). Human Gene Transfer, John Libbey Eurotext. [0245]
Telling G. C., S. Perera, O. M. Szatkowski and J. Williams (1994),
absence of an essential regulatory influence of the adenovirus E1B
19-kilodalton protein on viral growth and early gene expression in
human diploid WI38, HeLa, and A549 cells. J. Virol. 68, 541-7.
Tooze J. (1981), DNA Tumor Viruses (revised), Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y. [0246] Vieira J. and J.
Messing (1987), Production of single-stranded plasmid DNA, pp.
3-11, Methods in Enzymology, Acad. Press Inc. [0247] Vincent A. J.
P. E., M. d. C. Esandi, G. D. von Someren, J. L. Noteboom, C. J. J
Avezaat, C. Vecht, P. A. E. S. Smitt, D. W. von Bekkum, D. Valerio,
P. M. Hoogerbrugge and A. Bout (1996a), treatment of
Lepto-meningeal metastasis in a rat model using a recombinant
adenovirus containing the HSV-tk gene. J. Neurosurg. in press.
[0248] Vincent A. J. P. E., R. Vogels, G. von Someren, M. d. C.
Esandi, J. L. Noteboom, C. J. J. Avezaat, C. Vecht, D. W. von
Bekkum, D. Valerio, A. Bout and P. M. Hoogerbrugge (1996b), Herpes
Simplex Virus Thymidine Kinase gene therapy for rat malignant brain
tumors. Hum. Gene Ther. 7, 197-205. [0249] Wang K. and G. D.
Pearson (1985), adenovirus sequences required for replication in
vivo. Nucl. Acids Res. 13, 5173-5187. [0250] White E., A. Denton
and B. Stillman (1988), J. Virol. 62, 3445-3454. [0251] Yang Y., Q.
Li, H. C. J. Ertl and J. M. Wilson (1995), cellular and humoral
immune responses viral antigens create barriers to lung-directed
gene therapy with recombinant adenoviruses. J. Virol. 69,
2004-2015. [0252] Yang Y., F. A. Nunes, K. Berencsi, E. E. Furth,
E. Gonczol and J. M. Wilson (1994a), cellular immunity to viral
antigens limits E1-deleted adenoviruses for gene therapy. Proc.
Nat'l. Acad. Sci. USA 91, 4407-11. [0253] Yang Y., F. A. Nunes, K.
Berencsi, E. Gonczol, J. F. Engelhardt and J. M. Wilson (1994b),
inactivation of E2A in recombinant adenoviruses improves the
prospect for gene therapy in cystic fibrosis. Nature Genetics 7,
362-9. [0254] Zantema A., J. A. M. Fransen, A. Davis-Olivier, F. C.
S. Ramaekers, G. P. Vooijs, B. Deleys and A. J. van der Eb (1985),
localization of the E1B proteins of adenovirus 5 in transformed
cells, as revealed by interaction with monoclonal antibodies.
Virology 142, 44-58.
Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID
NOS: 22 <210> SEQ ID NO 1 <211> LENGTH: 21 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <221> NAME/KEY: <222> LOCATION: <223>
OTHER INFORMATION: Description of Artificial Sequence: Primer Ea-1
<400> SEQUENCE: 1 cgtgtagtgt atttataccc g 21 <210> SEQ
ID NO 2 <211> LENGTH: 21 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <221>
NAME/KEY: <222> LOCATION: <223> OTHER INFORMATION:
Description of Artifical Sequence: Primer Ea-2 <400>
SEQUENCE: 2 tcgtcactgg gtggaaagcc a 21 <210> SEQ ID NO 3
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <221> NAME/KEY:
<222> LOCATION: <223> OTHER INFORMATION: Description of
Artificial Sequence: Primer Ea-3 <400> SEQUENCE: 3 tacccgccgt
cctaaaatgg c 21 <210> SEQ ID NO 4 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <221> NAME/KEY: <222> LOCATION:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Primer Ea-5 <400> SEQUENCE: 4 tggacttgag ctgtaaacgc 20
<210> SEQ ID NO 5 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer Ep-2
<400> SEQUENCE: 5 gcctccatgg aggtcagatg t 21 <210> SEQ
ID NO 6 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <221>
NAME/KEY: <222> LOCATION: <223> OTHER INFORMATION:
Description of Artificial Sequence: Primer Eb-1 <400>
SEQUENCE: 6 gcttgagccc gagacatgtc 20 <210> SEQ ID NO 7
<211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <221> NAME/KEY:
<222> LOCATION: <223> OTHER INFORMATION: Description of
Artificial Sequence: Primer Eb-2 <400> SEQUENCE: 7 cccctcgagc
tcaatctgta tctt 24 <210> SEQ ID NO 8 <211> LENGTH: 27
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <221> NAME/KEY: <222> LOCATION:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Primer SV40-1 <400> SEQUENCE: 8 gggggatccg aacttgttta ttgcagc
27 <210> SEQ ID NO 9 <211> LENGTH: 25 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer SV40-2
<400> SEQUENCE: 9 gggagatcta gacatgataa gatac 25 <210>
SEQ ID NO 10 <211> LENGTH: 27 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer Ad5-1
<400> SEQUENCE: 10 gggagatctg tactgaaatg tgtgggc 27
<210> SEQ ID NO 11 <211> LENGTH: 24 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer Ad5-2
<400> SEQUENCE: 11 ggaggctgca gtctccaacg gcgt 24 <210>
SEQ ID NO 12 <211> LENGTH: 27 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer ITR1
<400> SEQUENCE: 12 gggggatcct caaatcgtca cttccgt 27
<210> SEQ ID NO 13 <211> LENGTH: 27 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer ITR2
<400> SEQUENCE: 13 ggggtctaga catcatcaat aatatac 27
<210> SEQ ID NO 14 <211> LENGTH: 32 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: PCR primer
PCR/MLP1 <400> SEQUENCE: 14 ggcgaattcg tcgacatcat caataatata
cc 32 <210> SEQ ID NO 15 <211> LENGTH: 32 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <221> NAME/KEY: <222> LOCATION: <223>
OTHER INFORMATION: Description of Artificial Sequence: PCT primer
PCR/MLP2 <400> SEQUENCE: 15 ggcgaattcg gtaccatcat caataatata
cc 32 <210> SEQ ID NO 16 <211> LENGTH: 17 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <221> NAME/KEY: <222> LOCATION: <223>
OTHER INFORMATION: Description of Artificial Sequence: PCT primer
PCR/MLP3 <400> SEQUENCE: 16 ctgtgtacac cggcgca 17 <210>
SEQ ID NO 17 <211> LENGTH: 50 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: PCT primer HP/asp1
<400> SEQUENCE: 17 gtacactgac ctagtgccgc ccgggcaaag
cccgggcggc actaggtcag 50 <210> SEQ ID NO 18 <211>
LENGTH: 50 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <221> NAME/KEY: <222>
LOCATION: <223> OTHER INFORMATION: Description of Artificial
Sequence: PCT primer HP/asp2 <400> SEQUENCE: 18 gtacctgacc
tagtgccgcc cgggctttgc ccgggcggca ctaggtcagt 50 <210> SEQ ID
NO 19 <211> LENGTH: 55 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <221>
NAME/KEY: <222> LOCATION: <223> OTHER INFORMATION:
Description of Artificial Sequence: PCT primer HP/cla1 <400>
SEQUENCE: 19 gtacattgac ctagtgccgc ccgggcaaag cccgggcggc actaggtcaa
tcgat 55 <210> SEQ ID NO 20 <211> LENGTH: 55
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <221> NAME/KEY: <222> LOCATION:
<223> OTHER INFORMATION: Description of Artificial Sequence:
primer HP/cla2 <400> SEQUENCE: 20 gtacatcgat tgacctagtg
ccgcccgggc tttgcccggg cggcactagg tcaat 55 <210> SEQ ID NO 21
<211> LENGTH: 5620 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <221>
NAME/KEY: Ad5 left terminus <222> LOCATION: 1..457
<220> FEATURE: <221> NAME/KEY: enhancer <222>
LOCATION: 458..969 <220> FEATURE: <221> NAME/KEY: exon
<222> LOCATION: 970..1204 <220> FEATURE: <221>
NAME/KEY: gene <222> LOCATION: 1218..2987 <220>
FEATURE: <221> NAME/KEY: polyA_signal <222> LOCATION:
3018..3131 <220> FEATURE: <221> NAME/KEY: pUC12
backbone <222> LOCATION: 3132..5620 <220> FEATURE:
<221> NAME/KEY: gene <222> LOCATION: 4337..5191
<223> OTHER INFORMATION: Description of Artificial Sequence:
Plasmid pICL <400> SEQUENCE: 21 catcatcaat aatatacctt
attttggatt gaagccaata tgataatgag ggggtggagt 60 ttgtgacgtg
gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg
180 gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg
gatgttgtag 240 taaatttggg cgtaaccgag taagatttgg ccattttcgc
gggaaaactg aataagagga 300 agtgaaatct gaataatttt gtgttactca
tagcgcgtaa tatttgtcta gggccgcggg 360 gactttgacc gtttacgtgg
agactcgccc aggtgttttt ctcaggtgtt ttccgcgttc 420 cgggtcaaag
ttggcgtttt attattatag tcaggggctg caggtcgtta cataacttac 480
ggtaaatggc ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac
540 gtatgttccc atagtaacgc caatagggac tttccattga cgtcaatggg
tggagtattt 600 acggtaaact gcccacttgg cagtacatca agtgtatcat
atgccaagta cgccccctat 660 tgacgtcaat gacggtaaat ggcccgcctg
gcattatgcc cagtacatga ccttatggga 720 ctttcctact tggcagtaca
tctacgtatt agtcatcgct attaccatgg tgatgcggtt 780 ttggcagtac
atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca 840
ccccattgac gtcaatggga gtttgttttg gcaccaaaat caacgggact ttccaaaatg
900 tcgtaacaac tccgccccat tgacgcaaat gggcggtagg cgtgtacggt
gggaggtcta 960 tataagcaga gctcgtttag tgaaccgtca gatcgcctgg
agacgccatc cacgctgttt 1020 tgacctccat agaagacacc gggaccgatc
cagcctccgg actctagagg atccggtact 1080 cgaggaactg aaaaaccaga
aagttaactg gtaagtttag tctttttgtc ttttatttca 1140 ggtcccggat
ccggtggtgg tgcaaatcaa agaactgctc ctcagtggat gttgccttta 1200
cttctagtat caagcttgaa ttcctttgtg ttacattctt gaatgtcgct cgcagtgaca
1260 ttagcattcc ggtactgttg gtaaaatgga agacgccaaa aacataaaga
aaggcccggc 1320 gccattctat cctctagagg atggaaccgc tggagagcaa
ctgcataagg ctatgaagaa 1380 atacgccctg gttcctggaa caattgcttt
tacagatgca catatcgagg tgaacatcac 1440 gtacgcggaa tacttcgaaa
tgtccgttcg gttggcagaa gctatgaaac gatatgggct 1500 gaatacaaat
cacagaatcg tcgtatgcag tgaaaactct cttcaattct ttatgccggt 1560
gttgggcgcg ttatttatcg gagttgcagt tgcgcccgcg aacgacattt ataatgaacg
1620 tgaattgctc aacagtatga acatttcgca gcctaccgta gtgtttgttt
ccaaaaaggg 1680 gttgcaaaaa attttgaacg tgcaaaaaaa attaccaata
atccagaaaa ttattatcat 1740 ggattctaaa acggattacc agggatttca
gtcgatgtac acgttcgtca catctcatct 1800 acctcccggt tttaatgaat
acgattttgt accagagtcc tttgatcgtg acaaaacaat 1860 tgcactgata
atgaattcct ctggatctac tgggttacct aagggtgtgg cccttccgca 1920
tagaactgcc tgcgtcagat tctcgcatgc cagagatcct atttttggca atcaaatcat
1980 tccggatact gcgattttaa gtgttgttcc attccatcac ggttttggaa
tgtttactac 2040 actcggatat ttgatatgtg gatttcgagt cgtcttaatg
tatagatttg aagaagagct 2100 gtttttacga tcccttcagg attacaaaat
tcaaagtgcg ttgctagtac caaccctatt 2160 ttcattcttc gccaaaagca
ctctgattga caaatacgat ttatctaatt tacacgaaat 2220 tgcttctggg
ggcgcacctc tttcgaaaga agtcggggaa gcggttgcaa aacgcttcca 2280
tcttccaggg atacgacaag gatatgggct cactgagact acatcagcta ttctgattac
2340 acccgagggg gatgataaac cgggcgcggt cggtaaagtt gttccatttt
ttgaagcgaa 2400 ggttgtggat ctggataccg ggaaaacgct gggcgttaat
cagagaggcg aattatgtgt 2460 cagaggacct atgattatgt ccggttatgt
aaacaatccg gaagcgacca acgccttgat 2520 tgacaaggat ggatggctac
attctggaga catagcttac tgggacgaag acgaacactt 2580 cttcatagtt
gaccgcttga agtctttaat taaatacaaa ggatatcagg tggcccccgc 2640
tgaattggaa tcgatattgt tacaacaccc caacatcttc gacgcgggcg tggcaggtct
2700 tcccgacgat gacgccggtg aacttcccgc cgccgttgtt gttttggagc
acggaaagac 2760 gatgacggaa aaagagatcg tggattacgt cgccagtcaa
gtaacaaccg cgaaaaagtt 2820 gcgcggagga gttgtgtttg tggacgaagt
accgaaaggt cttaccggaa aactcgacgc 2880 aagaaaaatc agagagatcc
tcataaaggc caagaagggc ggaaagtcca aattgtaaaa 2940 tgtaactgta
ttcagcgatg acgaaattct tagctattgt aatgggggat ccccaacttg 3000
tttattgcag cttataatgg ttacaaataa agcaatagca tcacaaattt cacaaataaa
3060 gcattttttt cactgcattc tagttgtggt ttgtccaaac tcatcaatgt
atcttatcat 3120 gtctggatcg gatcgatccc cgggtaccga gctcgaattc
gtaatcatgg tcatagctgt 3180 ttcctgtgtg aaattgttat ccgctcacaa
ttccacacaa catacgagcc ggaagcataa 3240 agtgtaaagc ctggggtgcc
taatgagtga gctaactcac attaattgcg ttgcgctcac 3300 tgcccgcttt
ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg 3360
cggggagagg cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc
3420 gctcggtcgt tcggctgcgg cgagcggtat cagctcactc aaaggcggta
atacggttat 3480 ccacagaatc aggggataac gcaggaaaga acatgtgagc
aaaaggccag caaaaggcca 3540 ggaaccgtaa aaaggccgcg ttgctggcgt
ttttccatag gctccgcccc cctgacgagc 3600 atcacaaaaa tcgacgctca
agtcagaggt ggcgaaaccc gacaggacta taaagatacc 3660 aggcgtttcc
ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg 3720
gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta
3780 ggtatctcag ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac
gaaccccccg 3840 ttcagcccga ccgctgcgcc ttatccggta actatcgtct
tgagtccaac ccggtaagac 3900 acgacttatc gccactggca gcagccactg
gtaacaggat tagcagagcg aggtatgtag 3960 gcggtgctac agagttcttg
aagtggtggc ctaactacgg ctacactaga aggacagtat 4020 ttggtatctg
cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat 4080
ccggcaaaca aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc
4140 gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc tacggggtct
gacgctcagt 4200 ggaacgaaaa ctcacgttaa gggattttgg tcatgagatt
atcaaaaagg atcttcacct 4260 agatcctttt aaattaaaaa tgaagtttta
aatcaatcta aagtatatat gagtaaactt 4320 ggtctgacag ttaccaatgc
ttaatcagtg aggcacctat ctcagcgatc tgtctatttc 4380 gttcatccat
agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac 4440
catctggccc cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat
4500 cagcaataaa ccagccagcc ggaagggccg agcgcagaag tggtcctgca
actttatccg 4560 cctccatcca gtctattaat tgtttgccgg aagctagagt
aagtagttcg ccagttaata 4620 gtttgcgcaa cgttgttgcc attgctacag
gcatcgtggt gtcacgctcg tcgtttggta 4680 tggcttcatt cagctccggt
tcccaacgat caaggcgagt tacatgatcc cccatgttgt 4740 gcaaaaaagc
ggttagctcc ttcggtgctc cgatcgttgt cagaagtaag ttggccgcag 4800
tgttatcact catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa
4860 gatgcttttc tgtgactggt gagtactcaa ccaagtcatt ctgagaatag
tgtatgcggc 4920 gaccgagttg ctcttgcccg gcgtcaatac gggataatac
cgcgccacat agcagaactt 4980 taaaagtgct catcattgga aaacgttctt
cggggcgaaa actctcaagg atcttaccgc 5040 tgttgagatc cagttcgatg
taacccactc gtgcacccaa ctgatcttca gcatctttta 5100 ctttcaccag
cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa 5160
taagggcgac acggaaatgt tgaatactca tactcttcct ttttcaatat tattgaagca
5220 tttatcaggg ttattgtctc atgagcggat acatatttga atgtatttag
aaaaataaac 5280 aaataggggt tccgcgcaca tttccccgaa aagtgccacc
tgacgtctaa gaaaccatta 5340 ttatcatgac attaacctat aaaaataggc
gtatcacgag gcctatgcgg tgtgaaatac 5400 cgcacagatg cgtaaggaga
aaataccgca tcaggcgcca ttcgccattc aggctgcgca 5460 actgttggga
agggcgatcg gtgcgggcct cttcgctatt acgccagctg gcgaaagggg 5520
gatgtgctgc aaggcgatta agttgggtaa cgccagggtt ttcccagtca cgacgttgta
5580 aaacgacggc cagtgccaag cttgcatgcc tgcaggtcga 5620 <210>
SEQ ID NO 22 <211> LENGTH: 45 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: stem_loop <222> LOCATION: 11..45
<223> OTHER INFORMATION: Description of Artificial Sequence:
Asp 718 hairpin <400> SEQUENCE: 22 gtacactgac ctagtgccgc
ccgggcaaag cccgggcggc actag 45
1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 22 <210>
SEQ ID NO 1 <211> LENGTH: 21 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer Ea-1
<400> SEQUENCE: 1 cgtgtagtgt atttataccc g 21 <210> SEQ
ID NO 2 <211> LENGTH: 21 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <221>
NAME/KEY: <222> LOCATION: <223> OTHER INFORMATION:
Description of Artifical Sequence: Primer Ea-2 <400>
SEQUENCE: 2 tcgtcactgg gtggaaagcc a 21 <210> SEQ ID NO 3
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <221> NAME/KEY:
<222> LOCATION: <223> OTHER INFORMATION: Description of
Artificial Sequence: Primer Ea-3 <400> SEQUENCE: 3 tacccgccgt
cctaaaatgg c 21 <210> SEQ ID NO 4 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <221> NAME/KEY: <222> LOCATION:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Primer Ea-5 <400> SEQUENCE: 4 tggacttgag ctgtaaacgc 20
<210> SEQ ID NO 5 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer Ep-2
<400> SEQUENCE: 5 gcctccatgg aggtcagatg t 21 <210> SEQ
ID NO 6 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <221>
NAME/KEY: <222> LOCATION: <223> OTHER INFORMATION:
Description of Artificial Sequence: Primer Eb-1 <400>
SEQUENCE: 6 gcttgagccc gagacatgtc 20 <210> SEQ ID NO 7
<211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <221> NAME/KEY:
<222> LOCATION: <223> OTHER INFORMATION: Description of
Artificial Sequence: Primer Eb-2 <400> SEQUENCE: 7 cccctcgagc
tcaatctgta tctt 24 <210> SEQ ID NO 8 <211> LENGTH: 27
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <221> NAME/KEY: <222> LOCATION:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Primer SV40-1 <400> SEQUENCE: 8 gggggatccg aacttgttta ttgcagc
27 <210> SEQ ID NO 9 <211> LENGTH: 25 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer SV40-2
<400> SEQUENCE: 9 gggagatcta gacatgataa gatac 25 <210>
SEQ ID NO 10 <211> LENGTH: 27 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer Ad5-1
<400> SEQUENCE: 10 gggagatctg tactgaaatg tgtgggc 27
<210> SEQ ID NO 11 <211> LENGTH: 24 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer Ad5-2
<400> SEQUENCE: 11 ggaggctgca gtctccaacg gcgt 24 <210>
SEQ ID NO 12 <211> LENGTH: 27 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer ITR1
<400> SEQUENCE: 12 gggggatcct caaatcgtca cttccgt 27
<210> SEQ ID NO 13 <211> LENGTH: 27 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: Primer ITR2
<400> SEQUENCE: 13 ggggtctaga catcatcaat aatatac 27
<210> SEQ ID NO 14 <211> LENGTH: 32 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: PCR primer
PCR/MLP1 <400> SEQUENCE: 14 ggcgaattcg tcgacatcat caataatata
cc 32 <210> SEQ ID NO 15 <211> LENGTH: 32 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <221> NAME/KEY: <222> LOCATION: <223>
OTHER INFORMATION: Description of Artificial Sequence: PCT primer
PCR/MLP2 <400> SEQUENCE: 15 ggcgaattcg gtaccatcat caataatata
cc 32 <210> SEQ ID NO 16 <211> LENGTH: 17 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <221> NAME/KEY: <222> LOCATION: <223>
OTHER INFORMATION: Description of Artificial Sequence: PCT primer
PCR/MLP3 <400> SEQUENCE: 16
ctgtgtacac cggcgca 17 <210> SEQ ID NO 17 <211> LENGTH:
50 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <221> NAME/KEY: <222> LOCATION:
<223> OTHER INFORMATION: Description of Artificial Sequence:
PCT primer HP/asp1 <400> SEQUENCE: 17 gtacactgac ctagtgccgc
ccgggcaaag cccgggcggc actaggtcag 50 <210> SEQ ID NO 18
<211> LENGTH: 50 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <221> NAME/KEY:
<222> LOCATION: <223> OTHER INFORMATION: Description of
Artificial Sequence: PCT primer HP/asp2 <400> SEQUENCE: 18
gtacctgacc tagtgccgcc cgggctttgc ccgggcggca ctaggtcagt 50
<210> SEQ ID NO 19 <211> LENGTH: 55 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: <222> LOCATION: <223> OTHER
INFORMATION: Description of Artificial Sequence: PCT primer HP/cla1
<400> SEQUENCE: 19 gtacattgac ctagtgccgc ccgggcaaag
cccgggcggc actaggtcaa tcgat 55 <210> SEQ ID NO 20 <211>
LENGTH: 55 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <221> NAME/KEY: <222>
LOCATION: <223> OTHER INFORMATION: Description of Artificial
Sequence: primer HP/cla2 <400> SEQUENCE: 20 gtacatcgat
tgacctagtg ccgcccgggc tttgcccggg cggcactagg tcaat 55 <210>
SEQ ID NO 21 <211> LENGTH: 5620 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: Ad5 left terminus <222> LOCATION:
1..457 <220> FEATURE: <221> NAME/KEY: enhancer
<222> LOCATION: 458..969 <220> FEATURE: <221>
NAME/KEY: exon <222> LOCATION: 970..1204 <220> FEATURE:
<221> NAME/KEY: gene <222> LOCATION: 1218..2987
<220> FEATURE: <221> NAME/KEY: polyA_signal <222>
LOCATION: 3018..3131 <220> FEATURE: <221> NAME/KEY:
pUC12 backbone <222> LOCATION: 3132..5620 <220>
FEATURE: <221> NAME/KEY: gene <222> LOCATION:
4337..5191 <223> OTHER INFORMATION: Description of Artificial
Sequence: Plasmid pICL <400> SEQUENCE: 21 catcatcaat
aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt
120 gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt
gacgtttttg 180 gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg
gttttaggcg gatgttgtag 240 taaatttggg cgtaaccgag taagatttgg
ccattttcgc gggaaaactg aataagagga 300 agtgaaatct gaataatttt
gtgttactca tagcgcgtaa tatttgtcta gggccgcggg 360 gactttgacc
gtttacgtgg agactcgccc aggtgttttt ctcaggtgtt ttccgcgttc 420
cgggtcaaag ttggcgtttt attattatag tcaggggctg caggtcgtta cataacttac
480 ggtaaatggc ccgcctggct gaccgcccaa cgacccccgc ccattgacgt
caataatgac 540 gtatgttccc atagtaacgc caatagggac tttccattga
cgtcaatggg tggagtattt 600 acggtaaact gcccacttgg cagtacatca
agtgtatcat atgccaagta cgccccctat 660 tgacgtcaat gacggtaaat
ggcccgcctg gcattatgcc cagtacatga ccttatggga 720 ctttcctact
tggcagtaca tctacgtatt agtcatcgct attaccatgg tgatgcggtt 780
ttggcagtac atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca
840 ccccattgac gtcaatggga gtttgttttg gcaccaaaat caacgggact
ttccaaaatg 900 tcgtaacaac tccgccccat tgacgcaaat gggcggtagg
cgtgtacggt gggaggtcta 960 tataagcaga gctcgtttag tgaaccgtca
gatcgcctgg agacgccatc cacgctgttt 1020 tgacctccat agaagacacc
gggaccgatc cagcctccgg actctagagg atccggtact 1080 cgaggaactg
aaaaaccaga aagttaactg gtaagtttag tctttttgtc ttttatttca 1140
ggtcccggat ccggtggtgg tgcaaatcaa agaactgctc ctcagtggat gttgccttta
1200 cttctagtat caagcttgaa ttcctttgtg ttacattctt gaatgtcgct
cgcagtgaca 1260 ttagcattcc ggtactgttg gtaaaatgga agacgccaaa
aacataaaga aaggcccggc 1320 gccattctat cctctagagg atggaaccgc
tggagagcaa ctgcataagg ctatgaagaa 1380 atacgccctg gttcctggaa
caattgcttt tacagatgca catatcgagg tgaacatcac 1440 gtacgcggaa
tacttcgaaa tgtccgttcg gttggcagaa gctatgaaac gatatgggct 1500
gaatacaaat cacagaatcg tcgtatgcag tgaaaactct cttcaattct ttatgccggt
1560 gttgggcgcg ttatttatcg gagttgcagt tgcgcccgcg aacgacattt
ataatgaacg 1620 tgaattgctc aacagtatga acatttcgca gcctaccgta
gtgtttgttt ccaaaaaggg 1680 gttgcaaaaa attttgaacg tgcaaaaaaa
attaccaata atccagaaaa ttattatcat 1740 ggattctaaa acggattacc
agggatttca gtcgatgtac acgttcgtca catctcatct 1800 acctcccggt
tttaatgaat acgattttgt accagagtcc tttgatcgtg acaaaacaat 1860
tgcactgata atgaattcct ctggatctac tgggttacct aagggtgtgg cccttccgca
1920 tagaactgcc tgcgtcagat tctcgcatgc cagagatcct atttttggca
atcaaatcat 1980 tccggatact gcgattttaa gtgttgttcc attccatcac
ggttttggaa tgtttactac 2040 actcggatat ttgatatgtg gatttcgagt
cgtcttaatg tatagatttg aagaagagct 2100 gtttttacga tcccttcagg
attacaaaat tcaaagtgcg ttgctagtac caaccctatt 2160 ttcattcttc
gccaaaagca ctctgattga caaatacgat ttatctaatt tacacgaaat 2220
tgcttctggg ggcgcacctc tttcgaaaga agtcggggaa gcggttgcaa aacgcttcca
2280 tcttccaggg atacgacaag gatatgggct cactgagact acatcagcta
ttctgattac 2340 acccgagggg gatgataaac cgggcgcggt cggtaaagtt
gttccatttt ttgaagcgaa 2400 ggttgtggat ctggataccg ggaaaacgct
gggcgttaat cagagaggcg aattatgtgt 2460 cagaggacct atgattatgt
ccggttatgt aaacaatccg gaagcgacca acgccttgat 2520 tgacaaggat
ggatggctac attctggaga catagcttac tgggacgaag acgaacactt 2580
cttcatagtt gaccgcttga agtctttaat taaatacaaa ggatatcagg tggcccccgc
2640 tgaattggaa tcgatattgt tacaacaccc caacatcttc gacgcgggcg
tggcaggtct 2700 tcccgacgat gacgccggtg aacttcccgc cgccgttgtt
gttttggagc acggaaagac 2760 gatgacggaa aaagagatcg tggattacgt
cgccagtcaa gtaacaaccg cgaaaaagtt 2820 gcgcggagga gttgtgtttg
tggacgaagt accgaaaggt cttaccggaa aactcgacgc 2880 aagaaaaatc
agagagatcc tcataaaggc caagaagggc ggaaagtcca aattgtaaaa 2940
tgtaactgta ttcagcgatg acgaaattct tagctattgt aatgggggat ccccaacttg
3000 tttattgcag cttataatgg ttacaaataa agcaatagca tcacaaattt
cacaaataaa 3060 gcattttttt cactgcattc tagttgtggt ttgtccaaac
tcatcaatgt atcttatcat 3120 gtctggatcg gatcgatccc cgggtaccga
gctcgaattc gtaatcatgg tcatagctgt 3180 ttcctgtgtg aaattgttat
ccgctcacaa ttccacacaa catacgagcc ggaagcataa 3240 agtgtaaagc
ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac 3300
tgcccgcttt ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg
3360 cggggagagg cggtttgcgt attgggcgct cttccgcttc ctcgctcact
gactcgctgc 3420 gctcggtcgt tcggctgcgg cgagcggtat cagctcactc
aaaggcggta atacggttat 3480 ccacagaatc aggggataac gcaggaaaga
acatgtgagc aaaaggccag caaaaggcca 3540 ggaaccgtaa aaaggccgcg
ttgctggcgt ttttccatag gctccgcccc cctgacgagc 3600 atcacaaaaa
tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc 3660
aggcgtttcc ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg
3720 gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc
tcacgctgta 3780 ggtatctcag ttcggtgtag gtcgttcgct ccaagctggg
ctgtgtgcac gaaccccccg 3840 ttcagcccga ccgctgcgcc ttatccggta
actatcgtct tgagtccaac ccggtaagac 3900 acgacttatc gccactggca
gcagccactg gtaacaggat tagcagagcg aggtatgtag 3960 gcggtgctac
agagttcttg aagtggtggc ctaactacgg ctacactaga aggacagtat 4020
ttggtatctg cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat
4080 ccggcaaaca aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag
cagattacgc 4140 gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc
tacggggtct gacgctcagt 4200 ggaacgaaaa ctcacgttaa gggattttgg
tcatgagatt atcaaaaagg atcttcacct 4260 agatcctttt aaattaaaaa
tgaagtttta aatcaatcta aagtatatat gagtaaactt 4320 ggtctgacag
ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc 4380
gttcatccat agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac
4440 catctggccc cagtgctgca atgataccgc gagacccacg ctcaccggct
ccagatttat 4500 cagcaataaa ccagccagcc ggaagggccg agcgcagaag
tggtcctgca actttatccg 4560 cctccatcca gtctattaat tgtttgccgg
aagctagagt aagtagttcg ccagttaata 4620
gtttgcgcaa cgttgttgcc attgctacag gcatcgtggt gtcacgctcg tcgtttggta
4680 tggcttcatt cagctccggt tcccaacgat caaggcgagt tacatgatcc
cccatgttgt 4740 gcaaaaaagc ggttagctcc ttcggtgctc cgatcgttgt
cagaagtaag ttggccgcag 4800 tgttatcact catggttatg gcagcactgc
ataattctct tactgtcatg ccatccgtaa 4860 gatgcttttc tgtgactggt
gagtactcaa ccaagtcatt ctgagaatag tgtatgcggc 4920 gaccgagttg
ctcttgcccg gcgtcaatac gggataatac cgcgccacat agcagaactt 4980
taaaagtgct catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc
5040 tgttgagatc cagttcgatg taacccactc gtgcacccaa ctgatcttca
gcatctttta 5100 ctttcaccag cgtttctggg tgagcaaaaa caggaaggca
aaatgccgca aaaaagggaa 5160 taagggcgac acggaaatgt tgaatactca
tactcttcct ttttcaatat tattgaagca 5220 tttatcaggg ttattgtctc
atgagcggat acatatttga atgtatttag aaaaataaac 5280 aaataggggt
tccgcgcaca tttccccgaa aagtgccacc tgacgtctaa gaaaccatta 5340
ttatcatgac attaacctat aaaaataggc gtatcacgag gcctatgcgg tgtgaaatac
5400 cgcacagatg cgtaaggaga aaataccgca tcaggcgcca ttcgccattc
aggctgcgca 5460 actgttggga agggcgatcg gtgcgggcct cttcgctatt
acgccagctg gcgaaagggg 5520 gatgtgctgc aaggcgatta agttgggtaa
cgccagggtt ttcccagtca cgacgttgta 5580 aaacgacggc cagtgccaag
cttgcatgcc tgcaggtcga 5620 <210> SEQ ID NO 22 <211>
LENGTH: 45 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <221> NAME/KEY: stem_loop
<222> LOCATION: 11..45 <223> OTHER INFORMATION:
Description of Artificial Sequence: Asp 718 hairpin <400>
SEQUENCE: 22 gtacactgac ctagtgccgc ccgggcaaag cccgggcggc actag
45
* * * * *